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Postmastectomy radiation therapy (PMRT) has been proven to decrease locoregional 
recurrence and increase survival for women with large tumors and/or node-positive 
disease. However, the clinical benefit of radiotherapy in the treatment of breast cancer 
must be balanced against the documented risk for early and late toxicity.  Adverse 
effects after breast irradiation have been reported in a range of organs with the skin 
being the most commonly affected during breast cancer radiation.  The focus of this 
thesis is to evaluate the skin reactions of postmastectomy breast cancer patients 
undergoing radiation therapy treatments and its dosimetric effects. The proteomic 
response of human skin cells after exposure to PMRT regimens and the expression of 
apoptotic biomarkers that reflect cell death or biology using multiplexed 
immunoassays have also been studied in depth. 
 
Accurate assessments of skin doses in PMRT are important to ensure sufficient dose 
to the surface target volume without excessive skin reaction.  In our first study, we 
assessed the accuracy of surface dose calculation by a clinically used 3D treatment 
planning system (TPS) and those measured by Thermoluminescence dosimeters 
(TLDs) in a customized chest wall phantom.  Dose accuracy of up to 2.21% was 
found.  The deviations from the calculated absorbed doses were overall larger when 
wedges and bolus were used. These findings suggest that 3D TPS is a useful and 
accurate tool to assess the accuracy of surface dose and that radiation treatment 
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accuracy can be accurately predicted for tangential treatment of the chest wall after 
mastectomy. 
 
Skin reaction is the most common side effects during breast cancer irradiation.  
Unfortunately, current clinical assessment of radiation induced skin changes is 
generally limited to clinician-based rating scales, which are usually not sufficient for 
quantitative and objective evaluations. In our study, we determined the usefulness of 
ultrasonography in the assessment of post radiotherapy skin changes in PMRT breast 
cancer patients.  Our results demonstrated statistical significant difference between 
the skin thickness of irradiated chestwall and the contral lateral non-irradiated breast 
and a predisposition to severe chronic reactions was found in patients with RTOG 
scoring of grade 1 and grade 2.   
 
Knowledge of the pathophysiology of the irradiated skin is important to understand 
the tolerance and cosmetic response of the human skin to radiation. Unfortunately the 
cellular radiation response of the skin to different radiation therapy treatment regimen 
has never been studied. The practice of radiotherapy would also greatly benefit from 
the discovery of biomarkers that correlate with symptoms and side effects pertaining 
to tissues within the irradiated volume.  We investigated the radiation induced 
apoptotic cell death and apoptotic proteins expression in human skin after exposure to 
PMRT regimens. There is strong evidence of cellular damaged and accumulation of 
apoptotic proteins caused by ionizing radiation and these are radiation dosage and 
fraction size dependent.   
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In summary, results derived from this thesis have demonstrated that radiation induced 
skin reaction in PMRT breast cancer patients can be accurately predicted using 
image-based technology and multiplexed immunoassays. Taken together, it is 
conceivable that in the near future these measures will be used to monitor therapeutic 
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Chapter One - Introduction 
 




Breast cancer is one of the most common cancers amongst women.  Its incidence in 
Singapore has risen significantly over the last two decades [Chia et al 2002] and is 
expected to continue to rise sharply through the years.  Published results by Chia et 
al. 2002, demonstrated that the age standardized incidence rates in Singapore 
increased from 46.1 to 53.1 cases per 100,000 persons per year from 1998 – 2002.  A 
separate report taken from the Singapore Cancer Registry showed a similar increasing 
trend for breast cancer in Singapore females between 2005 and 2009 (Table 1.1 & 
Figure 1.1).  Singapore has one of the highest age-adjusted breast cancer incidences 
in Asia with increasing incidence in women in their 50’s [J Tey 2008].  
 
Table 1.1 Ten most frequent cancers in Singapore females (%) between 2005-2009. 
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Figure 1.1 Ten most frequent cancers in Singapore females (%) between 2005-2009. 




Figure 1.2 Breast cancer in Singapore: incidence and age-standardized incidence rate 
1968 – 2007.  Singapore Cancer Registry Report No. 7 
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 Breast cancer is also the leading cause of death in Singapore women (Table 1.2 -
Singapore Cancer Registry Interim Report, Trends in Cancer Incidence in Singapore 
2005-2009).  Published results by Jara-Lazaro et al 2010, demonstrated that about 
1,100 new cases are diagnosed annually and approximately 270 women die in 
Singapore each year from breast cancer, translating to breast cancer diagnoses in 
about three women daily, with approximately three cancer deaths every four days. 
 
Table 1.2 Ten Most Frequent Cancer Deaths in Singapore Females, 2005-2009.  
Singapore Cancer  Registry Report No. 7 
 
 
Radiotherapy has played an important role in the treatment of breast cancer.  It is 
routinely employed in breast conservation therapy.  Its role as adjuvant therapy in 
selected patients undergoing mastectomy for stages I and II disease is evolving, and it 
has become an essential component of the combined modality approach for stage III 
disease. 
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Postmastectomy Radiotherapy (PMRT) to the chest wall and to the regional 
lymphatics has shown to decrease locoregional recurrence and increase survival for 
women with large tumors and/or node-positive disease.  [Overgaard 1997, Ragaz 
1997].  These studies showed that PMRT not only reduced local regional recurrence 
rates but also improved disease free and overall survival rates in premenopausal 
patients receiving chemotherapy.  
 
However, the success of these treatments depends on many factors such as patient 
characteristics, therapy modalities, treatment regimens and total radiation dose.  
Selection of the appropriate dose for all patients is based on a balance between 
minimizing the incidence of severe normal tissue complications and maximizing the 
probability of local control. Adverse effects after breast irradiation have been reported 
in a range of organs such as ischemic heart disease, pneumonities and pulmonary 
fibrosis, erythema, telangiectasia and ulceration of the skin. [Fuller 1992, Paszat 
1999] with skin being the most common tissue for which side effects occur secondary 
to  breast cancer irradiation. 
 
Acute side effects, such as erythema and desquamation of the exposed skin and 
mucosa, occur during or shortly after therapy, whereas depending on the dose and 
fractionation, late effects can be severe tissue alterations like fibrosis and 
talengiectasia, and secondary malignancies.   
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Breast skin toxicity during radiotherapy though reversible in the majority of cases, 
can affect the therapeutic strategy and worsen quality of life.  [Pires et al 2008]. A 
review of literature  [Margolin et al 1990 and Troetschel et al 1991] has shown that 
the development of a severe acute skin reaction such as moist desquamation 
substantially affects patients’ quality of life and requires considerable time and effort 
on the part of the nursing staff in caring for these patients during their radiation 
therapy.  Extensive moist desquamation after radiotherapy is also recognized 
significantly to increase the risk of developing late skin effects such as telangiectasia  
[Bentzen et al 1991]. If the acute skin reaction is very severe, unplanned breaks in the 
treatment schedule may be required.  Results are evident that either a prolongation in 
treatment time or a delay in initiating radiotherapy treatment may result in a reduction 
in local control and patients’ survival benefits [Buchholz 1993, Kurtz 1991].  
 
However the risk of skin toxicity and cosmesis must be weighed against local and 
regional recurrences. Insufficient radiation doses especially to the skin region have 
shown to increase local and regional recurrences [Bentzen 1991].   Local and regional 
recurrences are difficult to control once they occur.  Studies have shown that local 
recurrence of breast cancer on the chest wall after mastectomy occurs in 3% to 22% 
of patients, depending on primary size and location, ER status, presence of lymph 
node disease, and use of other adjuvant treatment. [Buchanan et al 2006, Magno et al 
1987]. Studies by  Donegan et al 1966 have also demonstrated that the skin overlying 
the tumour bed and mastectomy scar are the regions that are at greatest risk for 
recurrence, with the majority of chest wall failures occuring in these regions.  A 
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separate study by Gillilian et al showed 1999 all 60 patients with isolated chest wall 
recurrence eventually died from metastatic breast cancer.  Unfortunately, at present 
time the ability to predict an individual breast cancer patient’s response  and tolerance 
to radiation is limited and based mostly on tumor stage (TNM) and toxicity scoring.   
Acute and late radiation induced side effects are currently scored using criteria from 
the Common Terminology Criteria for Adverse Events (CTC-AE), Radiation Therapy 
Oncology Group (RTOG), Late Effects in Normal Tissues Subjective, Objective, 
Management and Analytic Scales (LENT-SOMA) or other scoring approaches.  
[Pavy 1995].   
 
In view of these problems, we conclude that accurate assessments of surface and 
superficial doses for chest wall radiotherapy are important to provide valuable 
information for clinical consideration to avoid near-surface recurrence and severe 
skin toxicity.    
 
While the skin dose for head-and-neck treatments have been well studied [Higgins et 
al 2007], less is known about the measurement of skin dose as well as its implications 
for chest wall radiotherapy.  There has been immersed interest among clinicians to 
determine better prognostic factors for acute and late skin reactions in radiotherapy 
patients so as to better predict the individual risk of adverse side effects.  If these 
individuals could be recognized in advance of treatment, the clinical radiotherapy 
regimes could be adjusted accordingly to optimize results.  However, accurate skin 
dose assessment is more challenging in this treatment geometry due to the tangential 
Chapter One - Introduction 
 
Page | 8  
 
beams and the large curvature of the chest and smaller chestwall thickness. This 
forms the first part of this study - to examine prognostic factors that can minimize the 
risk of skin complications while keeping breast cancer locoregional control rates high. 
 
The establishment of a predictive invitro assay for radiosensitivity has also been a 
goal in radiotherapy research.  Published postmastecomy radiotherapy studies show 
considerable variability in radiotherapy regimens which translates into a variation in 
the dose delivered to the skin and in turn, may have an impact on local recurrence 
rates and toxicity.  As such, the radiosensitivity of normal human skin cultures to 
postmastectomy radiotherapy regimes can help to predict the benefit and toxicity 
associated with postmastectomy radiotherapy.  Unfortunately the cellular radiation 
response of the skin to different RT treatment regimen has never been studied.   
 
Proteomic profiling of patients undergoing radiotherapy for postmastectomy breast 
cancer could provide unique biomarkers that reflect cell death or biology in tumor or 
normal tissues.  These could be used to monitor therapeutic response, and predict 
local control and toxicity.  This thesis also aims to investigate the proteomic response 
human skin cells to postmastectomy radiotherapy regimes and assess the variability 
of individual proteomic signatures using multiplexed immunoassays. 
   
1.1 AIMS AND OBJECTIVES OF THIS THESIS  
Accurate assessments of surface and superficial doses in chestwall radiotherapy are 
important to ensure sufficient dose to the surface target volume without excessive 
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skin reaction.  The principal objective of this thesis is to evaluate the skin reactions of 
postmastectomy breast cancer patients undergoing radiation therapy treatments and 
its dosimetric effects.    Secondly, to evaluate the proteomic response of human skin 
cells after exposure to postmastectomy radiation treatment regimens and the 
assessment of the variability of individual proteomic signatures.   
 
In the following chapter, a background about breast cancer and the role of radiation 
therapy in the treatment of postmastectomy breast cancer patients is provided.  
Complications of radiotherapy therapy are also discussed.  In chapter 3, the use of a 
3-Dimensional radiation treatment planning system to predict radiation skin dose in a 
customized postmastectomy phantom is described.  To measure chronic skin changes 
quantitatively, ultrasonographic evaluations were performed in patients who have 
gone through post-mastectomy irradiation and the methods and results are discussed 
in chapter 4.  In chapter 5, radiation induced apoptotic cell death and inflammatory 
cytokine proteins expression in human skin after exposure to postmastectomy 
radiation and treatment regimens are discussed.  A summary of the work and 
discussion of future experiments are described.  Future, long-term goals for this study 
would be to correlate clinical data in postmastectomy patients with our findings to 
allow better evaluation and prediction of the probability of undesirable effects of 
radiotherapy.    These measures can lead to prediction of skin reactions helping with 
the design of new treatment techniques and different dose fractionation schemes.   
This can greatly improve local control and disease free survival in patients with the 
use of postmastectomy radiotherapy.
Chapter Two- Background 
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2.1 OVERVIEW OF BREAST CANCER 
This section discusses the anatomy and management of clinically localized breast 
cancer. 
2.1.1 ANATOMY OF THE BREAST 
Located within the superficial fascia of the anterior thoracic wall, the breast is composed 
of 15 to 20 segments of glandular tissue of the tubuloalveolar type.  Each lobe is 
supported by fibrous connective tissue that forms a framework [Winchester DJ 2006].  
The fibrous connective tissues connect the segments with adipose tissues abundantly 
interspersed between the segments.  These segments compose the parenchyma and 
converge at the nipple in a radial fashion.  Subcutaneous connective tissues surround the 
gland and extend as septa between the segments, providing structural support for the 
glandular elements.  The deep layer of superficial fascia lies on the posterior surface of 
the breast adjacent to and at points fusing with the deep pectoral fascia of the chest wall.   
 
2.1.2 LYMPHATIC DRAINAGE 
Breast cancer spreads locally by direct infiltration of the surrounding parenchyma and 
may extend to underlying muscle and overlying skin, including the nipple.  A dense 
network of lymphatics in the skin may facilitate widespread cutaneous permeation by 
tumour. 
 
The most common sites of regional lymph node involvement in breast cancer are the 
axillary, internal mammary and supraclavicular regions.   
 
More than 75% of lymph from the breast passes to the axillary nodes with the remainder 
flowing into parasternal lymphatics.  The axillary nodes are thus the major site of 
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regional metastases from breast carcinoma, and approximately 40% of patients have 
histopathology evidence of spread to the axillary nodes at presentation. 
 
2.1.3. LOCAL INVOLVEMENTS  
The primary site of breast cancer is described by the quadrant of the breast that contains 
the carcinoma.  In one series of 696 patients [Wang 2002], 48% of the tumours were in 
the upper outer quadrant, 17% in the central region, 15% in the upper inner quadrant, 
11% in the lower outer quadrant, and 6% in the lower inner quadrant.  The frequency of 
a quadrant’s involvement is related to the proportion of breast tissue in that region.   
 
The spread of cancer through the breast has been described by Haagensen [Haagensen 
1986].  This spread occurs by direct infiltration into the breast parenchyma, along 
mammary ducts, and through the lymphatics.  Direct infiltration occurs by projections 
that have a characteristic stellate appearance.  If the cancer is untreated, involvement of 
skin and underlying fascia of the pectoralis muscle is common.  Intraductal components, 
which are frequently observed, may include more than one segment of the breast.  It is 
not clear whether this is spread of the primary cancer or a field cancerization that results 
in transformation of the ductal lining.  Because of the lymphatic spread vertically to the 
plexus of the pectoralis fascia and spread to the central subareolar region, cancer beyond 
the palpable mass may be present in the breast. 
 
2.1.4 RECURRENCE IN THE SKIN  
Patterns of failure analyses consistently identify the skin overlying the tumour bed and 
mastectomy scare as the regions that are at greatest risk for recurrence, with the majority 
of chest wall failures occurring in these regions [Donegan et al 1966].  Separate studies 
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by Huang et al have shown improved locoregional control in postmastectomy patients 
when sufficient skin dose was delivered.  Thus radiation dose to the superficial part of 
the chest wall, in particular the skin after mastectomy is associated with the probability 
of local control.  This leads us to our next section on the role of radiation therapy in 
improving the local control of breast cancer. 
 
2.2. ROLE OF RADIATION THERAPY 
Radiotherapy plays an integral role in the management of patients with breast cancer 
whether they present with localized or disseminated disease.   
 
The rationale for use of radiation therapy in the treatment of primary breast cancer is to 
prevent recurrence of cancer in the chest wall, skin, mastectomy scar and the regional 
nodes, including the axillary, supraclavicular and internal mammary nodes.  Local 
recurrence is often symptomatic; these recurrences can ulcerate and be a source of 
bleeding as well as pain and infection.  Furthermore, regional recurrence, particularly in 
the axilla and supraclavicular regions, can be symptomatic and cause significant pain 
from brachial plexus involvement.  However, recurrences in internal mammary nodes 
are infrequently detected.  Because the internal mammary chain is difficult to evaluate 
clinically, recurrence in this area is usually noted only when the patient presents with 
parasternal mass or ulceration.  Local and regional recurrences are difficult to control 
once they occur.   
 
The second goal of radiotherapy to the breast is to improve overall survival.  Careful 
selection of patients for irradiation is critical, given the potential for morbidity of the 
therapy.   
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Many randomized studies [Overgaard M 1999,Ragaz, et al. 1997] have demonstrated 
that postmastectomy radiation therapy improves locoregional recurrence and survival.  
As such, the following few sections aim to provide an-in-depth literature on 
postmastectomy radiation therapy. 
 
2.2.1 POSTMASTECTOMY RADIATION THERAPY 
Postmastectomy Radiation Therapy (PMRT) refers to the use of irradiation to the chest 
wall and draining lymph node regions as an adjuvant treatment after mastectomy.  There 
are three possible reasons for the use of PMRT.  The first is to reduce the rate of 
locoregional tumor recurrence (i.e. recurrence on the chest wall or in the axillary, 
internal mammary, or supraclavicular lymph nodes) by treatment residual microscopic 
disease that has spread beyond the margin of surgical resection.  It has been well 
documented that in the absence of PMRT, there is a substantial risk of local recurrence 
after modified radical (or even radical) mastectomy.  This risk is principally related to 
the presence and extent of axillary nodal involvement; if axillary nodes are involved, 
local recurrence is seen in approximately 25% of patients, whereas if axillary nodes are 
not involved, local recurrence is seen in approximately 5% of patients [Wong J S 2004].  
Therefore, PMRT can benefit high risk patients by preventing local recurrence. 
 
The second rationale for PMRT is to improve survival by eradicating residual local 
disease that is the only site of persistent cancer after mastectomy and a potential source 
of subsequent distant metastases.  Residual microscopic disease can potentially develop 
not only into clinically apparent local recurrence, but also into distant metastases via 
haematogenous spread. 
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The third rationale for PMRT is to improve survival by eradicating residual local disease 
after mastectomy and systemic therapy.  The hypothesis for this rationale is that such 
persistent local disease is a potential source of subsequent distant metastases.  Patients 
who have both systemic micro metastases and residual local disease after mastectomy 
might benefit from the use of postmastectomy radiotherapy. 
 
2.2.2 USE OF POSTMASTECTOMY RADIATION THERAPY WITH 
SYSTEMIC THERAPY 
A number of studies have examined the issue of addition postmastectomy RT to 
adjuvant chemotherapy [Overgaard et al 1997,  Wong et al 2004,  Overgaard M 2007].   
The largest of these are from the Danish Breast Cancer Cooperative Group (DBCCG).  
In the DBCCG trial 82b, 1,708 premenopausal patients who had undergone mastectomy 
for pathologic stage II or III breast cancer  were randomly assigned to eight cycles of 
chemotherapy CMF plus local regional RT or to nine cycles of CMF alone [Overgaard 
1999, Overgaard 2007].  With a median follow-up of 114 months, the 10 year rate of 
local regional recurrence (LRR) was reduced from 32% to 9% with RT, and overall 
survival improved from 45% to 54% with RT (both p<0.01).  In the DBCCG trial 82c, 
1,375 postmenopausal patients who had undergone mastectomy for pathologic stage II 
or III breast cancer were randomly assigned to tamoxifen for 1 year plus locoregional 
RT or to tamoxifen alone  [Overgaard M 1999, Overgaard 2007].  With a median follow 
up of 123 months, the 10 year rate of LRR was reduced from 35% to 8% with RT and 
overall survival was improved from 36% to 45% with RT (both p <0.05). 
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In a smaller trial from the British Columbia,  [Ragaz et al. 1997], 318 node positive 
premenopausal patients treated with modified radical mastectomy were similarly 
randomized to adjuvant CMF chemotherapy and post operative RT or chemotherapy 
alone.  The results of this trial were similarly to those of the DBCCG trial 82b. 
 
The results of the 2 Danish trials is the most relevant to this issue because of their study 
length, length of followup and large number of patients.  The magnitude of the survival 
improvemtn seen in these trials is similar to that seen with adjuvant systemic therapy 
and suggests that all node positive patients should receive postmastectomy RT.   
 
A meta-analysis of trials conducted in postmastectomy patients [Wong JS 2004] show a 
survival advantage to provide radiation to these patients.  However, the use of 
postmastectomy RT must be considered in relation to the risk of local recurence.  This 
risk clearly inceases with increasing nodal involvement.  Radiation therapy clearly 
improves local control in patients with a high risk of local recurence (> three node 
postive nodes), in addition to providing a survival benefit [Overgaard M 2007]. Other 
possible risk factors to consider include tumor size, margins extranodal extensions and 
age  [Pisansky TM 1993]. 
 
In summary, postmastectomy radiation therapy can be given to improve local control or 
to improve the likelihood survival.  The American Society for Radiation Oncology 
(ASTRO) recommends that patients with four or more positive lymph nodes receive 
postmastectomy RT to improve local control and survival [Harris JR 1999].  The 
American Society for Clinical Oncology (ASCO) published clinical practice guidelines 
in 2001, and its panel agrees with the routine use of postmastectomy RT for patients 
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with four or more positive nodes  [Recht A 2001].  The panel also suggest RT for 
patients with T3 tumours with any positive nodes as well as patients with operable stage 
III tumours.  No definitive recommendations could be made for patients with T1 or T2 
tumours and one to three positive nodes.  Similarly, the National Comprehensive Cancer 
Network recommends routine chest wall and nodal RT for patients with four or more 
positive nodes and consideration of RT for patients with one to three positive nodes.  
[National Comprehensive Cancer Network. 2003].  It also recommends chestwall RT for 
patients with tumours larger than 5cm margins or positive margins. 
 
2.2.3 RADIATION THERAPY TECHNIQUES AFTER MASTECTOMY 
The chest wall is usually treated with to a total dose of 46-50Gy.  The axilla and 
supraclavicular fossa are treated with the patient in the same position, but with separate 
anterior and posterior fields, matched to minimize any overlap with the tangential breast 
fields.   
 
Prior to the treatment of a patient, setup marks for daily reproducibility of patient’s setup 
position are drawn on the patient.  This is important to ensure patient’s position is 
reproduced daily for accurate delivery of radiation to the affected treatment site. 
However, the greatest challenge is the reliability of these skin marks as in most areas of 
the human body, skin moves over underlying tissues; thus setup marks on the skin may 
be unreliable.  It is therefore important to make setup marks on the skin distant from the 
breast tissue as shown in Figure 2.1 and more importantly, on the immobilization device.    
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Figure 2.1: Treatment marks on chest wall 
 
2.2.4. DEFINITION OF CLINICAL TARGET VOLUME  
Three important anatomic regions must be considered in target volume definition for 
postmastectomy patients – (a) the chestwall itself, (b) the internal mammary lymph node 
region and (c), the supraclavicular fossa/axilla. 
 
Placement of the medial field border is on the midline and the lateral border coincides 
with the mid-axillary line.  The inferior border is positioned 1cm inferior to the most 
inferior part of the contra lateral breast or surgical scar.  Superiorly, the tangential fields 
should ideally extend to the manubiosternal joint but may terminate inferior to this if the 
patient is unable to abduct her arm sufficiently. 
Conventionally, breast patients are treated in the supine position. The arm on the 
involved side is elevated above the head, with the face turned away from the involved 
side.   To irradiate the chestwall, most frequently used technique is the opposed 
tangential fields. This technique is illustrated in Figure 2.1.  The chestwall is treated 
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with a pair of tangential fields that enter and exit through the previously determined 
medial and lateral boarders of breast target volume as defined earlier.   
 
Figure 2.2 A tangential breast setup showing (a) medial and (b) lateral tangent fields 
[Bentel 1996] 
This is an isocentric technique for treatment of the chestwall, incorporating medial and 
lateral tangential glancing breast fields.  The clinical target volume is then marked on 
the patient using permanent markers. These treatment marks as shown in Figure 2.3 are 
to be left on the patient skin throughout the course of her treatment. 
 
Figure 2.3 Treatment marks drawn on patient. 
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2.2.5.  COMPLICATIONS OF RADIATON THERAPY 
Radiation therapy plays an important role in the management of breast cancer.  However 
the clinical benefit of irradiating the breast tissue must be weighed against the risk of 
severe toxicity.   The potential complications of radiation after either breast conserving 
surgery or mastectomy include arm edema, symptomatic pneumonitis, rib fracture, 
radiation related heart disease, brachial plexopathy, marked fibrosis or soft tissue 
necrosis and second malignancy [Fuller SA 1992].  The incidence of these 
complications is related to surgical and radiation technique and to the use of adjuvant 
systemic therapy [Ragaz, et al. 1997].  The next section looks at the skin and its 
interaction with radiation.  The acute and chronic skin reactions to irradiation will be 
discussed in depth. 
2.3 
22.22 
2.3. RESPONSE OF THE SKIN TO RADIATION DOSE 
During a standard radiation treatment schedule, skin reaction intensifies according to the 
escalating dose.  The extent of acute and chronic reactions of the skin to breast 
irradiation depends on several variables, including radiation dose and energy, dose 
fractionation and field size. Dryness and redness (erythema) of the skin are common 
after a skin dose of about 3000 cGy (3-4 weeks into treatment).  Dry desquamation, 
which involves flaking of superficial layers of the epidermis, may appear after the 
delivery of about 4000 cGy to the skin.  Moist desquamation, involving the loss of 
superficial and deep epidermal layers, occurs when doses to the skin exceed 5000 cGy.  
Moist desquamation may arise earlier in treatment in areas where skin folds or bolus 
intensify the prescribed dose.   
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2.3.1. ACUTE SKIN REACTIONS 
Mitotic inhibition appears 30 minutes after a single dose of 4-5 Gy and is followed by a 
decrease in the proliferation of the germinal layer of the endothelium.  The pathologic 
correlate of the erythema that begins to appear in the radiation therapy field within a few 
hours after irradiation is capillary dilatation and increased capillary permeability [Ang 
KK 2003].  As the radiation therapy continues, swelling and proliferation of capillary 
endothelial cells appear.  In the arterioles, the tunica intima and tunica media are 
disrupted after 2-3 weeks of radiation therapy.  The basal cells enlarge and show nuclear 
pyknosis [Fajardo LG 2001]. Maturing keratinocytes also show swelling, nuclear 
pyknosis, and cytoplasmic vacuolization.  The moist desquamation phase of acute 
radiodermatitis begins 3-4 weeks after treatment begins and manifests as vascular 
dilatation and hyperaemia, oedema, and extravasations of erythrocytes and leukocytes.  
Approximately 4 weeks after treatment begins, small superficial blisters may form, 
coalesce and rupture.   
 
Similar acute changes are seen in the adnexal structures of the skin and are caused by 
death of the rapidly dividing germinal layer of the epithelium.  Sebaceous glands and 
eccrine are highly sensitive to radiation which are responsible for the skin dryness that 
develops during treatment. 
 
Epidermal necrosis and ulceration can occur as early as 2 months after the start of 
radiation therapy.  There is an increasing trend of developing ulceration of the skin with 
the increasing high dose delivered to the breast. If irradiation produces mild necrosis of 
the subepidermis, the new epidermis that forms will be thinner than normal.  If the 
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necrosis is sufficient to cause disappearance of the basement membrane beneath the 
basal cells, the new epidermis will be highly susceptible to trauma, infection, and other 
stresses.  With more extensive necrosis associated with greater damage to blood vessels 
and connective tissue, repair may be largely by secondary intention (i.e. by replacement 
fibrosis).  When severe and deep necrosis of sub epidermal supporting tissues and larger 
blood vessels occurs, an ulcer may take months or even years to heal.  This may delay 
radiation treatment or even disrupt the treatment process. 
 
2.3.2 CHRONIC SKIN REACTIONS 
After radiation therapy, the decrease in the number of small blood vessels and the 
increase in the density and amount of fibrous tissue in irradiated regions gradually 
progress over time [Ang KK 2003].  The damaged vasculature and connective tissue 
continue to deteriorate, partly because of the treatment and partly because of aging and 
other acquired insults.  The irradiated epidermis remains chronically dry because of 
permanent damage to the sebaceous and eccrine glands.  Microscopic atrophy of the 
epidermis occurs, with loss of epidermal ridges and dermal papillae, a condition known 
as poikiloderma  [Fajardo LG 2001].  The basal layer shows few mitoses.  Capillaries, 
venules and lymphatic vessels are reduced innumber and often show telangiectases.  
Telangiectases result from loss of microvascular endothelial cells and damge to the 
basement membrane, leading to contractions of multiple capillary loops into a single 
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2.3.3. DOSE DISTRIBUTION IN SKIN 
Accurate assessments of surface and superficial doses in radiotherapy can provide 
valuable information for clinical consideration to avoid near-surface recurrence while at 
the same time limiting severe skin toxicity, especially for postmastectomy breast 
treatments.  However, surface dose depends in a complex way on several treatment 
parameters.  In general surface dose is found to decrease with an increase in photon 
energy, decrease in field size and increase in source to surface distance.  Wedges, blocks 
and compensators can significantly increase surface dose relative to open field 
situations.  Surface dose is also dependent on the angle of incidence of the beam with 
the surface [Biggs and Ling, 1979, Gerbi et al 1987, Lamb and Blak 1998, Lopex 
Medina et al 2005, Petti et al 1983, Yang et al 2004, Zhu and Palta 1998]. 
 
As such, accurate skin dose assessment is more challenging in this treatment geometry 
due to the tangential beams and the large curvature of the chest and smaller chestwall 
thickness.  In addition, the inaccuracy of calculations in the buildup region will also 
affect the doses given to the normal skin tissues and near surface tumours.  High energy 
photon beams are characterized by a dose buildup region, over which dose increases 
rapidly from the surface to a maximum value at some depth within the irradiated body.  
This is so called skin sparing effect of photon beam. 
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Figure. 2.4. Examples of central-axis depth-dose curves for (A) photon beams and (B) 
electron beams of various energies used in external beam radiation therapy. 
 
 
2.4. RADIATION PHYSICS ON PRODUCTION OF X-RAYS 
Dose computation in external beam radiotherapy predicts the dose produced by highly 
specialized linear-accelerator radiation sources.  A basic look at important aspects of 
megavoltage x-ray production and interaction is required to understand the dosimetry of 
radiation therapy on postmastectomy breast cancer patients. There are 2 types of 
interactions that result in the production of X-rays, characteristic radiation production 
and Bremsstrahlung radiation.  Modern megavoltage linear accelerators use the 
Bremsstahlung process to generate MeV x rays beams used for Radiotherapy. 
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2.4.1. CHARACTERISTIC RADIATION 
When an electron strikes an atom and causes the inner shell electron to leave the atom as 
shown in Figure 2.5, the outer shell electron “jumps” in to fill the place of the excited 
electron thereby emitting a photon.  The photon emitted is known as the characteristic x-
ray.  Figure 2.6 shows the emission of characteristic x-ray. This process depends on the 
Z value of the atom. If the difference is large, if the K or L shell or one in a high Z atom, 
an x-ray photon is emitted.  For a low Z atom, a light photon emerges.  The frequency of 














Figure 2.6   The emission of characteristic X-ray. 
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2.4.2. BREMSSTRAHLUNG 
If an incoming high energy electron interacts with the nucleus’ electric field causing the 
electron to change its direction or velocity, then the change in direction or velocity 
results in a change in the kinetic energy of the electron.  This deceleration (“braking”) 
results in the emission of an X-ray photon.  The initial electron leaves the atom with less 
energy than it had when it entered.  The process is known as Bremsstrahlung ( Figure 
2.7). 
 
Figure 2.7   A Bremstrahlung interaction 
 
The production of bremsstrahlung occurs when the high energy electrons produced by 
the accelerator strike a target, usually consisting of tungsten.  The size of the region 
from which primary photons are produced is one to a few millimeters.  The dose builds 
up from the skin of the patient because of the increased number of charged particles 
being set in motion distal to the patient’s surface.  The dose builds up to a maximum 
depth , dmax, characteristic of the photon beam energy. This results in a low skin dose 
which may result in local recurrences in postmastectomy breast cancer patients.   
Inner orbital  
electron 
X-ray emitted 
Incoming high speed 
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2.4.3 DOSE COMPUTATION USING 3D MONTE CARLO RADIOTHERAPY 
TREATMENT PLANNING SYSTEM ALGORITHMS 
 
The accuracy of calculating radiation dose distribution in radiotherapy treatment 
planning is a crucial component in the treatment process if the dose delivered to the 
patient is not to differ from the prescribed dose by more than 3 to 5% [ICRU 1976, 
Brahme et al 1988, Cunningham 1982].  The majorities of modern 3D treatment 
planning system algorithms is based on the superposition/convolution pencil beam 
method [Boyer and Mok 985, Mackie et al 1985, Mohan et al 1986, Ahnesjo et al 1987, 
Keall and Hoban 1996] and have superseded the traditional 2D algorithms. 
 
Complex photon and electron dose calculation algorithms such as full Monte Carlo, 
macro Monte Carlo etc. are able to incorporate full knowledge of the attributes of the 
radiation beam in the input of their calculation.  This enables greater accuracy to be 
achieved at the planning stage, and the properties of the clinical beams to be used are 
accurately known [Ebert et al 1996].  It is generally accepted that the Monte Carlo 
technique is the most accurate method of calculating dose distributions in three 
dimensions as it directly simulates the individual interactions at an interface between 
heterogeneous media.  Furthermore, if the Monte Carlo calculation utilizes the photon 
spectra obtained from a full model of the linear accelerator radiation treatment head, the 
accuracy of the three dimensional dose distributions is improved.  With this in mind, all 
the treatment planning algorithms utilized in our study was full Monte Carlo to ensure 
its dose computation accuracy.
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3.1. INTRODUCTION 
Local recurrence in the chest wall is a common mode of treatment failure in patients 
with locally advanced breast cancer after mastectomy, and occurs in 3-22% of cases 
depending on the size, location, and ER status of the primary disease, presence of 
regional lymph node metastasis, and use of adjuvant treatment [Buchanan et al 2006, 




Skin overlying the tumour bed and mastectomy scar are at the 
highest risk of local recurrence [ Donegan et al 1966] . 
 
Radiation therapy is a commonly utilized modality for adjuvant treatment in patients 
with locally advanced breast after mastectomy. Results from randomized trials have 
demonstrated that postmastectomy radiotherapy improves prognoses including overall 
survival in patients with locally advanced breast cancer [Overgaard 1999, Ragaz et al 
1997]. It is generally accepted that the improvement in treatment outcome including 
disease-free survival (DFS) and overall survival (OS) is secondary to, at least in part, 
improved local control.   
 
Skin doses have always been an important factor in the dose prescription for 
postmastectomy radiotherapy.  Radiation dose to the superficial part of the chest wall 
including the skin after mastectomy is associated with the probability of local control 
[Wong 2004, Bentzen et al 1991]. Prospective randomized studies [Donegan et al 1966, 
Wong 2004, Bentzen et al 1991, Huang et al 2006]
 
have demonstrated the effectiveness 
of a skin boost in reducing the risk of local recurrence even with negative margins after 
postmastectomy irradiation.  Sufficient surface dose can thus improve local control and 
minimise local recurrence. 
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However, skin toxicity secondary to radiotherapy is one of the most frequent observed 
adverse effects after postmastectomy irradiation. Although reversible in the majority of 
cases, skin toxicity can affect the therapeutic strategy and adverse effect patients’ quality 
of life [Pires et al 2008].  
 
Dose at the surface of the radiation field such as skin in the postmastectomy cases is 
primarily due to electron contamination [Klein et al 1993, Parthasaradhi et al 1989].  It 
is affected by field size, angle of beam incidence, air gap and the use of beam modifiers 
[Hsu et al 2008]. Accurate skin dose assessment is particularly challenging in the post-
mastectomy chest wall due to the tangential beams and the large curvature of the chest 
and the limited chestwall thickness.  Inaccuracy of calculations in the buildup region 
will also affect the doses given to the normal skin tissues and for potential disease 
control near skin surface.   
 
As both local disease control and the prevalence and severity of skin toxicity are 
radiation dose-related, knowledge of skin dose is clearly important to identify areas 
where unwanted skin reactions can be expected and to ensure that structures at risk of 
recurrence receive the prescribed dose. While the accuracy of skin dose measure by 
commercially available radiation planning system has been confirmed in irradiation for 
head-and-neck disease [Higgins et al 2007], such accuracy on the chest wall has not 
been confirmed in post-mastectomy radiation therapy.  
 
Thermoluminescence dosimetry (TLD) measurements is a proven reliable method for 
the verification of many of the dosimetric aspects associated with external beam 
radiotherapy [Essers et al 1999, Herbert et al, Kron 1994 and Lee et al 1994].  It is the 
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gold standard dosimetry program recommended for quality assurance of machine 
calibration, planning dosimetry and dose calculation.  The purpose of this study was to 
assess the accuracy of surface dose calculation in post-mastectomy radiation by 
comparing the surface dose predicted by a clinically used treatment planning systems 
and those measured by TLDs in a customised chestwall phantom.  
 
3.2. MATERIALS AND METHODS 
 
3.2.1. CONSTRUCTION OF MASTECTOMY PHANTOM 
This study involves the construction of a chest wall phantom for skin dose assessment. 
As most commercially available radiation therapy anthropomorphic phantoms have very 
thick chest wall measuring at least 5cm or more.  It thus cannot be used to accurately 
provide skin dose measurement for postmastectomy patients whose chest wall thickness 
was measured to range from 2-5cm only [Ramsey et al 1998].
 
 
The phantom is constructed of materials designed to conform to the requirements of 
ICRU Report NO. 44. The densities of the structures in the phantom, which model lung 
tissue, have a mass density of 0.32g/cm
3
, which is similar to normal lung density.  The 
entire phantom was manufactured using wax from a mould made from a template taken 
from the transversal CT slices of a mastectomy patient. The selection of wax material 
was used, as it has similar mass density of normal tissue.  The phantom is capable of 
having thermoluminescent dosimeter (TLD) materials inserted at various locations to 
enable dose assessment.  Chest wall thickness and lung volume was measured using CT 
transversal slice of a postmastectomy patient. (Figure 3.1) 
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Figure 3.1 Chest wall thickness and lung measured using CT transversal slice 
 
The phantom was then constructed according to the curvature of the lung and chestwall 
using wax and cork material. (Figure 3.2) 
 
Figure 3.2  A customised chestwall phantom using wax and cord material 
 
 
   
Chest wall 
thickness 
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3.2.2. THERMOLUMINESCENCE DOSIMETER PLACEMENTS AND 
INVIVO DOSIMETRY 
 
Seven TLDs were distributed throughout each right breast phantom to give adequate 
representation of dose distribution including the superior and inferior planes relative to 
the central axis (z=0) where greater dose inhomogeneity is known to occur.  (Superior 
and inferior planes used were z = +6cm and -6cm).   
 
These 7 positions were chosen to avoid regions of potential dose gradient and to reflect 
the dose delivered to the surface of chestwall.  Each plane has 3 separate TLD positions 
(Figure 3.3).  The TLDs were placed in customised cavities that were individually 
moulded to fit the TLD chip thickness at the surface and entrance dose region.  Surface 
dose is here defined as the dose measured at a distance less than 5mm below the 
patient’s skin and entrance dose region is measured at a distance dmax (1.5cm for the 
6MV beam) below the patient’s surface.  In order to assess the reproducibility of the 
measurements, the absorbed dose measurement with TLDs was repeated 5 times for 
each region. 
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Figure 3.3 A display of TLD positions on the mastectomy phantom 
 
A cross sectional displays of TLD positions for the phantom are presented in Figure 3.4 
and 3.5.  Note that the customised phantom has a thin chest wall and a crescent-shaped 
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Figure 3.4 - Schematic representation of the TLD positions 
 
TLD measurement with 1cm  Bolus  
TLD measurements are repeated with placement of 1cm bolus over the chestwall. 
Similarly 7 TLDs were placed under the bolus. 
 
Figure 3.5 Schematic representations of the TLD positions on a phantom with 1cm 
Bolus 
 
Chapter Three – A Dosimetric study on the use of radiation therapy treatment planning 
system to predict for surface doses in postmastectomy radiation therapy patients  
 
Page | 36  
 
The customised mastectomy phantom underwent CT scanning for dose planning, using 
the same procedures as those for a patient.  In this particular case, a set of scans, 3mm 
was acquired, which will make dose calculations in any cross section through the target 
volume possible. 
 
3.2.3 THERMOLUMINESCENT DOSIMETERS (TLD) 
The TLD chips used for the study were hot pressed LiF chips (3.1 x 3.1 x 0.9mm) read 
on an automated TLD reader (Realto Automatic TLD 1A Processor, Nuclear 
Enterprises, UK) and annealed in a TLD oven.  The TLD chips underwent regular 
uniformity measurements in order to monitor reproducibility and estimate each chip’s 
relative response.  The annealing protocol was 1 h of heating at 400
0
C followed by 2 h at 
100 
0
C.  The chips were then read by the automated reader and annealed again for re-
use.  Before commencing the study, the TLD chips were individually calibrated in 
groups of 10 and were kept in the same group to ensure each TLD is as identical as 
possible. 
 
3.2.4. TREATMENT PLANNING SYSTEM 
A CMS  XiO
®
  3D treatment planning system (Elekta CMS software Inc.) was used for 
this investigation. All treatment fields included lateral tangential fields using 6MV 
photons and a virtual wedge of 10 degrees was used for contour compensation.   Point 
doses from the Xio
®
 Treatment planning system were calculated for each relevant TLD 
positions.  The use of lung correction was taken into account.  Surface and buildup dose 
values were calculated by determining the peak dose along the central axis of each 
defined field using point-dose estimates from the planning system.  For comparison with 
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possible off axis positioning of TLDs, surface and buildup dose values were also 
calculated at off-axis locations as described above. 
 
The convolution/superposition algorithm was use for the tangential breast calculations.  
Treatment plans were generated using 8 x 16cm
2
 tangential fields at beam angles of 50 
and 230 to simulate a chest wall treatment for a presribed dose of 200cGy.   
 
 
3.2.5. STATISTICAL ANALYSIS 
SPSS version 17 was the statistical tool used for data analysis.  The measurements of 
each of the seven TLD readings were compared with corresponding points obtained by 
treatment planning system by using a one sample t-test. This test determined the 
significance of differences between the values of the same measurements made under 
the two different conditions (measured doses by TLDs vs calculated doses by Treatment 
planning system (TPS). A p value < 0.05 (one tailed) was considered significant. 
 
3.3. RESULTS 
All values are a representation of the combined contribution from both medial and 
lateral tangential beams.  The distribution of the deviations between TLD and calculated 
radiation dose was considered.  The measurements were also analysed with the use of 
wedges and the presence of bolus.  The results of the measurements are presented in 
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3.3.1. SURFACE DOSES BETWEEN ABSORBED DOSES (TLD) AND 
CALCULATED DOSES (TPS) 
 
Table 3.1: The mean surface dose measurements of all 7 positions as measured in the 
customised mastectomy breast phantom.  The doses relate to 2 Gy given as mean target 
dose in the breast. 
Surface Dose measurements 
 
 Plans without Bolus or 
Wedge (Control)  
Plan with 1cm Bolus  
 
Plan with Wedge  
 











(%) and P 






(%) and P 







(%) and P 
















(p=0.183) 1.91 1.95 
-2.09 
(p=0.181) 1.56 1.55 
0.72 










(p=0.308) 1.93 1.95 
-0.57 
(p=0.305) 1.61 1.64 
-1.56 









(p=0.230) 2.06 2.10 
-1.88 
(p=0.307) 1.91 1.94 
-1.63 










(p=0.103) 2.15 2.15 
-0.20 
(p=392) 1.90 1.94 
1.64 









(p=0.351) 1.94 1.95 
-0.42 
(p=0.390) 1.94 1.93 
0.65 










(p=0.078) 2.07 2.07 
0.18 
(p=0.455) 1.90 1.9 
0.19 




































*A single-sample t test was performed on SPSS ver 17. P values significant only if 
p<0.05 (one tailed) 
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Figure 3.6 - TLD vs TPS surface dose (buildup) with 1cm bolus; 
 
 




Fig 3.6  
Fig 3.7 
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3.3.2. ENTRANCE DOSE AT THE BUILD-UP REGION BETWEEN 
ABSORBED DOSES (TLD) AND CALCULATED DOSES (TPS) 
 
Table 3.2:  The mean entrance dose (buildup region) measurements of all 7 positions 
as measured in the customised mastectomy breast phantom.  The doses relate to 2 Gy 
given as mean target dose in the breast 
 
*A single-sample t test was performed on SPSS ver 17. P values significant only if 
p<0.05 (one tailed) 
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Figure 3.10- TLD vs TPS entrance dose (dmax) with wedge 
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Figure 3.11- TLD vs TPS entrance (dose (dmax) with 1cm bolus and wedge 
  
 
Table 3.1 and 3.2 shows the surface doses between absorbed dose (TLD) and calculated 
doses (TPS) in different slices through the mastectomy breast phantom. In general, there 
is no significant difference between measured absorbed dose and calculated doses by the 
treatment planning system (p value >0.05 (one tailed).  Dose accuracy of up to 2.21% is 
obtained.  The deviations from the calculated absorbed doses are overall larger when 
wedges and bolus are used, 3.4%.   
 
With 1cm bolus, significant skin dose buildup was seen.  Table 3.1 shows the surface 
dose without bolus and with 1cm bolus material.  Surface dose without bolus is much 
smaller than that with bolus. The net result is that, at 1 cm bolus, skin doses are 
approximately 39% higher at surface.  The calculated skin dose at similar points show 
similar results although readings were slightly higher 45%.    
Fig 3.11 
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Table 3.2 shows the entrance dose at the build-up region (1.5cm depth) between 
absorbed dose (TLD) and calculated doses (TPS) in the mastectomy breast phantom.  
Result show lesser dose variation in dmax region with variations between calculated and 
measured readings in the main cross-section of the breast reduced to 2.56% only.   
 
The measured absorbed doses in the whole target volume are in general lower than 
calculated levels and the differences are larger when wedges and bolus are used as beam 
modifiers and compensators.  The measured dose distribution also shows a smaller 
variation than the calculated one.   
 
3.4. DISCUSSIONS 
The objective of this study was to investigate whether it was possible to use radiation 
therapy treatment planning systems (TPS) to accurately predict the radiation skin dose in 
postmastectomy radiotherapy patients.  The calculated radiation skin dose by TPS was 
compared with actual measured dose by 7 small TLDS placed in a customised 
mastectomy phantom. Although results show some degree of variations between these 2 
dose measurements, however, the discrepancies in our study is small with dose 
variations up to 2.56%. This is in good agreement with a recent study by Mijnheer at el 
1991
 
who recommends a 2-3.5% degree of accuracy.  Redpath et al 1992 carried out a 
similar study in a range of situations using geometric phantoms and they have also 
obtained an agreement of 2-3%.  
 
However when compared with similar studies done on breast region, our studies 
demonstrated different results. Our results differed from previous studies by 
Westermann et al 1984 and Knoos 
 
et al 1986 in which it is reported that tangentially 
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applied fields may give an overestimation of the dose calculation of up to 8%.   This can 
be easily explained due to current improved 3D treatment planning algorithms and faster 
computers as compared to studies done in 1980s. 
 
Skin toxicity is one of the most frequent adverse reactions that occur in patients 
submitted to postmastectomy radiotherapy.  The results obtained from this study are 
important as accurate surface dose and entrance dose determination allows the sequential 
checking of the dosimetry aspects over the whole treatment chain, the assessment of the 
quality of a given irradiation technique and the control of the dose delivery in 
individuals [Cozzi et al 1998]. The ability to estimate the surface and superficial dose 
with radiation therapy treatment planning systems can provide valuable information for 
clinical consideration to avoid near-surface recurrence while at the same time limiting 
severe skin toxicity, especially for postmastectomy chestwall treatments.  As discussed, 
studies have showed that the skin overlying the tumour bed and mastectomy scar are the 
regions that are at greatest risk for recurrence, with the majority of chest wall failures 
occurring in these regions [Donegan 1966].  A separate study by Huang et al 2006 has 
shown improved locoregional control in postmastectomy patients when sufficient skin 
dose is delivered.  
 
Improved surface dose prediction can also improve local control and minimise local 
recurrence [Buchanan et al 2006].
   
If these individuals could be recognized in advance 
of treatment, their clinical radiotherapy regimes could be adjusted accordingly to 
optimize results, and this will be effective in achieving a significant improvement in 
quality and outcome of breast treatments in mastectomy patients. 
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Many studies have focused on the skin dose for head and neck tumours.  For example, 
Lee et al 2002 identified severe skin reactions in some patients receiving IMRT for head 
and neck cancer.  They found that the average increase of the skin dose was about 18% 
due to the bolus effect of a thermoplastic mask material and the skin doses with masks 
were 84% and 100% of the prescribed dose for opposed lateral and extended field. They 
concluded that potential contributions to the increased skin dose are the bolus effect of 
the head and neck and shoulder mask, the use of multiple oblique beams and the 
inclusion of the skin as part of the target volume.  Higgins et al 2007 investigated 
delivery technique differences and found that the maximum surface doses of head and 
neck delivery was different when treated with bilateral fields, tomotherapy and IMRT, 
respectively.  Based on previous studies, many factors affect the doses of the skin and 
near-surface tumour eg. the use of bolus, oblique incident angle and delivery technique.  
While factors affecting the skin dose for head and neck treatments have been studied, 
little is known for chest wall radiotherapy.   
 
For chestwall tangential radiotherapy, 1cm bolus is often used during the treatment 
course to ensure adequate dose to the target volume which includes the skin but may be 
removed if deemed clinically necessary when skin toxicity occurs.  Our study evaluated 
the effect of 1cm bolus on the surface dose as well.  The surface dose with bolus was 
determined to be much larger than that without bolus as expected (39% increase in dose 
when bolus was used).  The calculated skin dose by TPS at similar points show similar 
results although readings were slightly higher 45%.   In comparison to a recent study by 
Quach et al 2000, they found that the surface dose with 1cm bolus increased by 54% 
compared to the dose without bolus on a chest wall phantom. Because of the different 
thickness and curvature of the phantom used, our increase rates were different from 
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Quach et al.  The effect of the bolus material on the surface dose is thus dependent on 
the different geometry and thickness of the chestwall.   
 
As can be observed, the treatment geometry due to the tangential beams, the use of 
wedges and the large curvature of the chest make surface dose prediction difficult.  
However, our results and recent studies by Spenzi  et al 2008 and Quach et al 2000  have 
shown that accurate clinical dose calculation can be computed by radiation therapy 
treatment planning systems, provided that the radiation source and the patient anatomy 
are modelled correctly.  This explains the use of a customised mastectomy phantom in 
our study  to model the exact treatment geometry of postmastectomy breast patients so 
as to produce higher degree of radiation treatment planning accuracy. 
 
It is important to recognize the limitations of this research.  Main limitation of our study 
is the use of only seven TLD positions placed throughout the mastectomy phantom.  
Ideally a larger number of TLDs placed throughout the phantom would be more 
desirable; however this was not necessary as these 7 positions were evenly distribution 
throughout the chestwall, thus accurate interpolation of any points within the chestwall 
can be made to reflect the dose delivered to the skin.  These 7 positions were also 
carefully chosen to avoid regions of potential dose gradient and scatter. The ability to 
accurately position the TLDs on the curved phantom’s surface for each irradiation was 
also a challenge.  Accurate TLD placement is an important factor in determining 
measured dose. Studies by Herbert et al 2003 have shown that TLD positioning errors 
would lead to changes in measured dose due to changes in SSD (source to surface 
distance) due to patient contour, changes in wedge transmission and variation in 
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response of the TLDs.  To avoid TLD placement error, each set of TLD positions was 
repeated 5 times.  Average of the 5 readings was taken for analysis. 
 
Radiation skin dose of postmastectomy patients could be more accurately studied in vivo 
in patients instead of the use of a mastectomy phantom.  However, the phantom model 
utilized is constructed with radiologically-equivalent material for both soft tissue and 
lungs. It is equipped with holes in grid form, which provides access for the TLD chips.  
These holes allowed for measurements to be taken in the buildup region, as well as at 
various depth of the chestwall, which would not be possible in vivo - postmastectomy 
patients.  The mastectomy phantom was specially constructed for this experiment, as 
most commercially available radiation therapy anthropomorphic phantoms have very 
thick chestwall measuring at least 5cm or more.   It thus cannot be used to accurately 
provide skin dose measurement for postmastectomy patients whose chestwall thickness 
was measured to range from 2-5cm only [Ramsey et al 1998].   Lastly, as this study was 
done completely using a phantom model, actual patient’s movement and breathing was 
excluded.  As such we are not sure if our results would differ with actual radiation doses 
measured in vivo in patients. 
 
3.5. CONCLUSION AND FUTURE DIRECTION 
The goal of this research was to provide clinicians information about the accuracy of 
surface dose prediction by radiation therapy planning systems in postmastectomy breast 
patients.  This is of great importance so as to obtain knowledge of skin dose to identify 
areas where unwanted skin reaction would be expected or to make sure that structures at 
risk of recurrence receive their prescribed doses.   Our studies have shown that radiation 
treatment accuracy expressed as a comparison between calculated doses (by TPS) and 
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measured doses (by TLD dosimetry) can be accurately predicted for tangential treatment 
of the chestwall after mastectomy.  
 
As we have studied and valided our radiation therapy treatment planning system as an 
accurate prediction tool for surface dose measurements, an immediate application is to 
evaluate clinical skin reactions in postmastectomy patients. Future work includes the 
correlation of clinical data in postmastectomy patients with predicted doses by radiation 
therapy planning systems to allow better evaluation of the probability of undesirable 
effects of radiotherapy.  These measures can lead to prediction of skin reactions helping 
with the design of new treatment techniques and different dose fractionation schemes.  If 
the design of new treatment techniques can aim to control the dose to various points 
according to likelihood of recurrence, this can greatly improve local control and disease 
free survival in patients with the use of postmastectomy radiotherapy. 
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4.1. INTRODUCTION  
 
Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer 
deaths among women worldwide [Kols 2002].  In addition to the acknowledged 
advances in surgical and medical therapies, the role of radiotherapy continues to remain 
important for all stages of breast cancer. While its role as adjuvant therapy in selected 
patients undergoing mastectomy for stages I and II disease is currently evolving, it has 
however, become an essential component of the combined modality approach for stage 
III disease. Postmastectomy radiotherapy (PMRT) to the chest wall and to the regional 
lymphatics has shown to decrease loco regional recurrence and increase survival for 
women with large tumors and/or node-positive disease [Overgaard 1999, Overgaard et al 
1999, Ragaz et al 1997, Recht et al 2001].  These studies showed that PMRT not only 
reduced local regional recurrence rates but also improved disease free and overall 
survival rates in premenopausal patients receiving chemotherapy.  
 
In spite of the advances in radiotherapy techniques, early and late adverse effects after 
breast irradiation are reported in a range of organs and tissues.  Some of these adverse 
effects include ischemic heart disease, pneumonities and pulmonary fibrosis, erythema, 
telangiectasia and ulceration of the skin [Fuller et al 1992, Paszat 1999] with skin being 
the most commonly affected area during breast cancer irradiation. While early effects 
can heal almost completely, the severe delayed changes that follow such as dermal 
atrophy, fibrosis, retraction and susceptibility to necrosis remain, and may affect the 
function and physical properties of the skin [Archambeau et al 1995, Hopewell 1990].  
Acute skin complications in postmastectomy patients have been well studied [Fernando 
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et al 1996, Harper et al 2004, Bentzen et al 1991], but little is known about risks of long 
term skin complications and cosmesis of these patients. This forms the basis of our 
study.  
 
Long term skin complication such as fibrosis is a common late side effect of 
radiotherapy treatment for breast cancer patients and is considered to be a dose-limiting 
factor during the therapy.  Quantitative and objective assessment of late skin reactions is 
helpful for oncologists and clinicians to estimate the efficacies of radiotherapy regimens 
or prediction of cosmesis outcome of these patients  
 
Previous studies on radiation induced skin effects have shown that skin assessments 
have been either descriptive or have used subjective parameters for scaling radiation 
effects [Fernando et al 1996, Harper et al 2004].
 
The visual assessments of skin 
condition are carried out subjectively by the examining physician and it is well known 
that the estimation of the visible changes by different examiners can be significantly 
biased [Dische et al 1989]. 
 
While the European Organization for Research and 
Treatment of Cancer (EORTC) and Radiation Therapy Oncology Group (RTOG) 
[Emami et al 1991] have an elaborate scoring system for acute skin reactions, evaluation 
of late skin changes are more descriptive, and there is no scoring to convey the amount 




As such, a quantitative assessment and documentation of late post radiation skin 
reactions are important for following up of PMRT patients.  
 
Chapter Four –An ultrasonographic evaluation of skin thickness in breast cancer patients 
after postmastectomy radiation therapy in postmastectomy radiation therapy patients  
 
Page | 57  
 
 
Quantitative methods that have been used to monitor skin changes following radiation 
therapy include direct evaluation of the mechanical properties of irradiated skin by the 
measurement of tensile strength of skin specimens or healing wound scars [Baker et al 
1989, Gorodetsky et al 1990], measurement of skin erythema by optical means 
[Turesson 1976, Nias 1963, Russel et al 1994], evaluation of skin water content by 
measurement of its dielectric constant [Nuutinen et al 1998] and examination of skin 
thickness by ultrasonic imaging [Baker et al 1989, Warszawski 1998]. Among the many 
methods, high resolution ultrasound of the skin has proven to be a precise and validated 
method used in many skin assessment studies following radiotherapy [Warszawski 
1998, Fornage et al 1993]. It enables accurate and easily reproducible determination of 
the skin’s subcutaneous thickness [Russell et al 1994] and allows real-time examination 
of the skin with relatively lower cost compared with other procedures such as biopsy and 
MRI.   
 
Applications of ultrasound reported in dermatology are generally based on the 
measurements of skin thickness [Alexander et al 1979].
 
Such measurements have been 
applied to assess various skin conditions particularly fibrosis. Gottllober et al 1997 used 
the change of skin thickness as an indicator of cutaneous fibrosis in their studies on five 
patients with cutaneous radiation syndrome. Huang et al 2007 also reported a significant 
change of skin thickness in the head and neck region after radiotherapy using 20MHz 
ultrasound. All these studies demonstrated the potential use of the ultrasound detection 
of skin thickness in assessing the post irradiation reactions of the skins. It is potentially 
helpful to use the ultrasonic properties to characterize the irradiated skin fibrosis because 
some changes of the skin structures are induced by therapeutic irradiation.  
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However, few clinical data were available in the literature for documenting the 
ultrasonic properties of fibrotic skin in vivo for postmastectomy breast cancer patients 
with radiation induced fibrosis.  Therefore, this study aimed to (1) measure chronic skin 
changes quantitatively using ultrasound, in patients who have gone through 
postmastectomy irradiation, and (2) determine if there is any correlation between late 
skin findings and acute visible changes using the CTC scoring criteria in 
postmastectomy patients.  
 
4.2. METHODS AND MATERIALS  
4.2.1. PATIENTS SELECTION 
This study utilized the records of National Healthcare Group (NHG) from National 
University Hospital (NUH) and Tan Tock Seng Hospital (TTSH), Singapore to identify 
a group of female patients previously treated at these institutions for PMRT from 
January 2004-December 2005. Two hundred and five patient records were identified 
from the database. Of these, 7 patients had deceased, the data of 94 patients were not 
complete (absence of CTC scoring in the five weeks of treatment), 26 were not 
contactable due to invalid addresses or telephone numbers, 16 patients had bilateral 
mastectomy, lumpectomy on the contra-lateral breast or metastases and 30 patients 
declined to participate in the study. This left 32 patients eligible to be invited to 
participate in the study. All of those patients were of Asian origin.   
 
The primary criteria used to select patients from the data obtained from NUH and TTSH 
included a total mastectomy with no bilateral involvement and should have completed 
full course of radiotherapy and chemotherapy treatments. Radiotherapy dosages and 
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CTC scoring were explicitly specified on the fifth treatment of each of the five treatment 
weeks and six cycles of adjuvant intravenous chemotherapy; CMF (cyclophosphamide, 
methotrexate and 5-fluorouracil) were delivered following the radiotherapy. The contra-
lateral breast which was not irradiated was categorized as control. Patients who had 
lumpectomy on the non irradiated breast and breast reconstruction on one side or 
bilaterally, and who had previous radiotherapy to the chest wall, either as definitive 
treatment or as entry/exit dose from previous intra-thoracic malignancy radiotherapy 
were excluded from the study.  
This investigation was approved by the institutional ethics review board -National 
Health Group (NHG) Domain-Specific Review Board (DSRB). Patient Information 
Sheet including the reasons and the details of the study as well as an invitation to 
participate in the study was mailed to the subjects. Patient’s Informed Consent form was 
signed by the patient on the same day of the ultrasound scan, prior to the scan.  
 
4.2.2. POSTMASTECTOMY BREAST RADIATION THERAPY 
All patients were 3D planned using 3D Xio Treatment planning system. The patients 
were positioned supine with elevated arms, flexed elbows supported by a wingboard. A 
high pillow was used to support the knees to ensure patient fixation during radiotherapy. 
Prior to radiotherapy, all patients had treatment marks drawn using a permanent marker 
which extended from the second costal cartilage down to 1 cm inferior to the contra-
lateral non-irradiated breast. The medial margin forms the midline and the lateral margin 
the mid-axillary line (Figure 4.1). Three permanent tattoos were used in the central 
treatment plane as a guide to reproduce the treatment marks, when necessary.  
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Fi
gure 4.1: Treatment marks on the patient 
 
The whole breast had been irradiated using opposed tangential fields with 6 MV photons 
covering the axillary and the infra-and supra-clavicular areas for all patients. The total 
dose was 46-50 Gy administered in daily doses of 2 Gy 5 days a week using a Siemens 
Primus, linear accelerator (Siemens Medical Systems, USA). Wedges and bolus of 1 cm 
thickness were used every day in all patients to optimize the homogeneity of the dose 
distribution.  
4.2.3. ULTRASOUND MEASUREMENTS  
To measure the skin thickness, ultrasound was performed using a Sequoia® 512 scanner 
(Siemens Medical Systems, USA) with a linear array transducer (15L8W). The 52mm 
foot print transducer has a wide bandwidth with a 14 MHz centre frequency and can 
achieve a maximum depth of 80mm. The “Breast Detail” preset was selected to give the 
settings discussed in Table 4.1. All the scans were performed using a special 
magnification mode without substantial loss of resolution (RES-mode) to have clearer 
details and precise measurements of the skin.  
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Table 4.1: Relevant Equipment Settings for the ‘Breast Detail’ preset 
 
After informed consent was taken, the patients were requested to lie supine on the 
couch. The treatment field points were reproduced with the aid of the patients’ case 
notes and the presence of permanent tattoos which had been marked in the central 
Power  0dB, Mechanical Index=1.6: As Low As Reasonably Achievable to 
minimize bio-effects.  
Time Gain 
Compensation (TGC)  
Adjusted to compensate the effect of attenuation in the subcutaneous 
tissue at greater depths in order to produce images of uniform brightness.  
Dynamic Range  66dB permits best differentiation between subtle changes in echo 
intensities of the skin region.  
Persistence  2 used to provide optimum smoothening of images with minimum 
movement induced artifacts.  
Post-processing  Options range from low (0) to high (3) contrast. It was at 2 to obtain 
optimal level of contrast.  
Overall Gain  Set at 2dB to demonstrate tissues with appropriate brightness.  
Edge  +2 to emphasize the boundaries between tissues.  
Delta  Δ2 for high contrast resolution.  
Spatial Compounding  A form of frame averaging. SC1 selected to maximize frame rate.  
Frame Rate  Decreases with increasing the scan depth, the number of focal zones and 
image line density (resolution). Varies during the scan but it should not 
be below 10Hz (fps).  
Focal Zone  Single focal zone placed at the level of the skin to optimize lateral 
resolution.  
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treatment plane during the treatment. Nine points for ultrasonic measurements within the 
medial, central and the lateral areas of the treatment field as well as the corresponding 
points in the contra-lateral non-irradiated breast were marked as shown in Figure 4.2 and 
Figure 4.3.  
  
 
A shadow found in the scar region can limit the ultrasound evaluation (Figure 4.4). If the 
measurement points fell on the mastectomy scar, the points were marked 1cm superiorly 
or inferiorly to the original points. The corresponding points were also marked on the 
contra-lateral non-irradiated breast to achieve measurement consistency.   
 
Figure 4.4: Scar causes shadowing  
Figure 4.2: Representation of points on 
the chest wall and contra-lateral breast 
Figure 4.3: Points marked on the chest 
wall and contra-lateral breast prior to 
ultrasound 
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All ultrasonic measurements were obtained using the slightest transducer force on the 
skin, by ensuring the transducer rested on the thick layer of gel to avoid affecting skin 
thickness (Figure 4.5). All patients were scanned by the same sonographer to reduce 
inter-operator error.  
 
Figure 4.5: Transducer resting on the thick layer of gel on the skin 
 
The axis of the transducer was kept perpendicular to the surface of the skin while 
scanning to maximize specular reflection at the skin/ subcutaneous tissue interface 
(Figure 4.6). All the points marked were individually scanned in the transverse plane. 
The full skin thickness (epidermis plus dermis) from the anterior echogenic border of the 
epidermis to the posterior echogenic border of the dermis was measured in B-mode. All 
images were stored in the hard-drive of the ultrasound machine for analyses. As a 
reference measurement, examination of the contra-lateral non-irradiated breast was 
carried out at the same time. This was a blind study whereby the sonographer was not 
aware of the retrospective collected data of the CTC acute scoring.  
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Figure 4.6: Echogenic border between the skin and the subcutaneous tissue 
 
4.2.4. STATISTICAL ANALYSES  
The measurements of each of the nine points of irradiated skin were compared with 
corresponding points of non-irradiated skin by using a t-test. This test determined the 
significance of differences between the values of the same measurements made under 
the two different conditions (postmastectomy with radiation skin thickness versus non-
irradiated contra-lateral skin thickness). These measurements obtained in the radiated 
breast were compared to the retrospective data of the peak acute CTC scoring obtained 
during the treatment weeks by utilizing a t-test. A p value < 0.05 was considered 
significant.  
 
4.3. RESULTS  
The median age of patients at the time of ultrasound scan was 52.5 years (range 37 to 68 
years). The median interval between the last radiotherapy treatment and current 
ultrasound scan was 27.5 months (range 16 to 39 months).  
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4.3.1. SKIN THICKNESS ON THE MASTECTOMY SIDE WITH RADIATION 
IN COMPARISON TO THE NON-IRRADIATED BREAST 
 
The skin thickness was reduced in the irradiated chest wall compared to the contra-
lateral non-irradiated breast (Table 4.2 and Table 4.3).  
Table 4.2: Reduced mean skin thickness on the Right mastectomy side with 
radiation in comparison to the Left non-irradiated breast.  
 
STATISTICS 
 Side  
 




Skin thickness  cm    Right Mastectomy 117 .1712 .03392 .00314 
 Left Control 117 .1845 .04089 .00378 
 
*The sample size N =117 refers to the 9 measurement points taken in 13 Right Sided 
mastectomy patients.   
 
Table 4.3: Reduced mean skin thickness on the Left mastectomy side with radiation 
in comparison to the Right non-irradiated breast 
STATISTICS 
 Side  
 




Skin thickness  cm    Left Mastectomy 171 .1764 .03184 .00243 
 Right Control 171 .1835 .02584 .00198 
 
* The sample size N=171 refers to the 9 measurement points taken in 19 Left Sided 
mastectomy patients.  
 
The mean total skin thickness inclusive of the epidermis and the dermis of the right 
irradiated side was 0.1712 cm (±0.03392 cm) compared with the left non-irradiated 
breast which was 0.1845 cm (±0.04089 cm; p=0.007). The left irradiated skin had a 
mean skin thickness of 0.1764 cm (±0.03184 cm) compared with the right non-irradiated 
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breast which was 0.1835 cm (±0.02584 cm; p=0.025). These independent t-tests 
produced a significant difference of reduced skin thickness on the right irradiated chest 
wall, p=0.007 (p<0.05) and left irradiated chest wall ρ=0.025 (p<0.025) in comparison 
to the non-irradiated skin thickness investigating chronic skin reactions.  
 
4.3.2. CORRELATIONS OF ACUTE SKIN SCORING (CTC) AND FIBROTIC 
THICKNESS  
 
Skin thickness for grade 1 and grade 2 of skin toxicity was compared in this study. Other 
grades were not included as there was only one patient representing grade 0 and grade 3 
respectively and none of grade 4. Patients with grade 2 acute skin toxicity presented 
with thinner skin compared to patients with grade 1. The mean skin thickness for 
patients who had grade 2 was 0.1720 cm (±0.03132 cm), while for grade 1 it was 0.1879 
cm (±0.03900 cm, p=0.006).  
 
Measurements between irradiated and non-irradiated breast (contra-lateral), show that 
the skin on the medial aspect measured at points 1, 4 and 7 was consistently thicker than 
the lateral aspect measured at the marked points of 3, 6 and 9 (Table 4.4).  A total of 3 
points from both medial (points 1, 4 and 7) and lateral (points 3, 6, and 9) aspect of the 
breast was measured. Total N = 32 patients x 3 points (total) = 96 from each side. 
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Table 4.4: Skin thickness of points marked on the medial and lateral side 
STATISTICS 
 Side  
 




Skin thickness on 
contralateral non-
irradiated breast  cm    
Medial 96 .1947 .02440 .00249 
 Lateral 96 .1773 .02988 .00305 
Skin thickness on 
mastectomy irradiated 
side 
Medial 96 .1960 .03330 .00340 
 Lateral 96 .1669 .03716 .00379 
 
*The sample size N=96 refers to 3 measurement points taken from each side of the 32 
patients  
 
4.4. DISCUSSION  
In this study we demonstrated quantitative ultrasound as an objective means of assessing 
late skin toxicity in postmastectomy breast cancer patients after radiation therapy. Huang 
et al 2007
 
has demonstrated that skin thickness measured via ultrasonic imaging proved 
to be a reliable quantitative and noninvasive measure to provide diagnostically useful 
information for an in vivo assessment of skin fibrosis. Using this as a feasible study, 
skin thickness was measured as a proxy for radiation induced fibrosis and edema in 32 
postmastectomy breast cancer patients who received full course of radiation therapy in 
our department. This is one of the few studies of its kind on postmastectomy breast 
cancer patients follow up comparing late skin effects particularly radiation induced 
fibrosis with acute scoring. To the best of our knowledge, there is limited literature 
available about radiation induced fibrosis after postmastectomy radiotherapy in 
ultrasonic imaging. This study attempted to provide some basic clinical results for this 
purpose.  Our study has shown that there is a statistically significant difference between 
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the skin thicknesses of the irradiated chest wall and the contra-lateral non-irradiated 
breast and a predisposition to chronic reactions was found in patients with acute CTC 
scoring of grade 1 and grade 2. These differences could assist to explain breast 
reconstruction complications in postmastectomy breast cancer patients after receiving a 
course of radiotherapy. A number of studies have demonstrated an increased rate of 
breast reconstruction complications after postmastectomy radiotherapy [Hussien et al 
2004, Behranwala et al 2006, Gui et al 2005, Tallet et al 2003].  Tallet et al 2003 
reported breast reconstruction complications were significantly greater in patients who 
received radiotherapy than those who did not (51% vs 14%) and a study by Behranwala 
et al  2006 suggested that the rate of capsular contracture due to radiation might be as 
high as 40%. As such most complications were either due to capsular contracture with or 
without pain, or skin fibrosis due to radiation exposure.  
 
In an effort to explain the increased breast reconstruction complications in patients due 
to increased radiation dose to the skin, a separate pilot study (results submitted for 
publication) was conducted in our department to assess skin dose in post-mastectomy 
radiation measured by TLDs in a customized chest wall phantom. The measurements 
were also analyzed with the use of wedges and the presence of bolus. The surface dose 
with bolus was determined to be much larger than that without bolus as expected (39% 
increase in dose when bolus was used).  
 
In addition, results showed that the oblique incident angle and flat chestwall thickness 
also played an important factor in increasing the skin dose in postmastectomy patients. 
As severity of skin toxicity is radiation-dose related, this suggests a possible relationship 
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with breast reconstruction complications and an impairment of the skin thickness with 
radiation due to skin fibrosis.   
 
The accuracy of the ultrasonic measurement of skin thickness has been established since 
the late 1970s [Alexander et al 1979]. By introducing this method in our study, we found 
that the breast skin thickness decreased significantly in the postmastectomy patients 
after radiotherapy. In our study, the skin thickness of the postmastectomy breast cancer 
patients was approximately 9.2% to 9.6% smaller than that of the control non-irradiated 
side. This is in contrast to previous publications [Gottlober et al 1997, Warszawski 
1997] that reported an increase of 37% in the neck region and 38% in the conservatively 
managed breast following irradiation. One possible reason for the discrepancies was the 
difference of radiation dosage used for the patients. Another possible reason was the 
difference of the follow-up time of the subjects at recruitment.  
Our proposed mechanism was supported by Warszawski et al 1997 who reported that 
structural changes occurring after radiotherapy depend on the time interval between the 
completion of treatment and ultrasonic examination. Fibrosis is a common late side 
effect of radiotherapy treatment for cancer patients and is considered to be a dose-
limiting factor.  It has been reported that the latency of fibrosis is between 2-3 years post 
radiotherapy and the severity of fibrosis progresses over time. Usually the skin first 
becomes erythematous due to desquamation (Figure 4.7), then thinned due to inadequate 
cell proliferation in the basal layer [Small et al 2006].  If damage is too severe, the skin 
will break down and ulcerate due to depletion of the regenerating cells in the basal layer 
[Bomford 2003].  In a group of 106 patients with lumpectomy followed by radiotherapy 
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were examined by Leucht et al 1988 using ultrasound, the time between completion of 
radiotherapy and the ultrasound examination ranged from 3 weeks to 8 years. Skin 
thickness was noted to initially increase then decrease after 2 years. Another study 
reported by Calkins et al 1988 examined twenty-one breast cancer patients who had 
undergone segmental resection and radiation therapy. The authors also observed an 
increase in skin thickness followed by a decrease in four of nine patients for whom serial 
ultrasound scans were performed beginning one to forty eight months after their 
radiation. A review of literature [Calkins et al 1988, Trotti et al 2000] have shown that 
majority of patients assessed were those following conservative surgery and irradiation.  
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4.4.1. CORRELATIONS OF ACUTE SKIN SCORING (CTC) AND FIBROTIC 
SKIN THICKNESS  
 
Skin reactions occurring within a time interval of up to three months following 
irradiation are defined as early reactions and reactions presenting after three months 
following irradiation are defined as late reactions [Paszat et al 1999]. There is a well-
established process of visual assessment of acute skin reactions using CTC Scoring 
[Trotti et al 2000]
 
which is carried out subjectively by the examining physician (Table 
4.5). The acute toxicity analyzed in this study was the peak score recorded during the 
weekly assessment at the end of every radiotherapy treatment.  
 
Table 4.5: CTC Scoring Criteria for Acute Radiation Skin Reactions  
 
CTC Scoring Criteria Skin Changes 
0 No change over baseline 
1 Follicular, faint or dull erythema, epilation, dry 
desquamation, decreased sweating 
2 Tender or bright erythema, patchy moist 
desquamation, moderate oedema 
3 Confluent, moist desquamation other than skin 
folds, pitting oedema 
4 Ulceration haemorrhage, necrosis 
 
In this study, grade 1 acute skin reaction was found in 72 % of patients, grade 2 in 22 % 
of patients and grade 3 and grade 0 were found in 3% each. No patient had grade 4 skin 
reaction in the study. These results are similar to those reported in literature whereby 
Back et al 2004 demonstrated a low rate of acute toxicity with a CTC score of 3 and 4 
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which occurred in only 6% of women receiving radiotherapy. Small and Woloschak 
2006 also added that on average, more than 80% of acute skin toxicity during breast 
radiation was in the grades of 1 and 2.   
 
In our study we correlated acute CTC with their measured skin thickness and 
demonstrated that patients with higher grade of acute skin reactions; i.e., grade 2, 
demonstrated reduced skin thickness as compared to those patients with grade 1 reaction 
in Table 4.6.  
 
Table 4.6: Reduced mean skin thickness in patients with grade 2 acute skin 
reactions 
Group Statistics 
grade N Mean Std. Deviation Std. Error 
Mean 
Skin thickness              grade 1 
  cm                                  grade 











*The sample size N=207 refers to the 9 measurement points taken in 23 patients with 
Grade 1 and N=63 refers to the 9 measurement points taken in 7 patients with Grade 2.  
 
On ultrasound, the skin appears echogenic and is well demarcated from the underlying 
hypoechoic subcutaneous fat. However, the epidermis cannot be resolved from the 
dermis on ultrasound. The epidermis is composed of several layers. The stratum basale 
is the deepest layer where the majority of cell division occurs. This layer is the most 
sensitive for radiation injury that results in the clinically visible acute radiation skin 
reactions [Mellor et al 2004].
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In addition, we also looked at the variation in skin thickness across the breast. The 
medial and lateral aspects of both sides were examined symmetrically. Our results 
showed that the skin on the medial aspect was consistently thicker than the lateral aspect 
on both the irradiated postmastectomy and non-irradiated side. This reported mean 
thickness is similar to previous studies by Wratten et al 2000
 
that compared variation in 
skin thickness in the conservatively managed breast. This finding suggests a need to use 
the same examination point when performing serial and comparative examinations.  
 
The results of this study may be limited because of small study population and non-
representation of patients with all the grades of CTC scoring. Our study has a low 
incidence of other grades of reactions especially higher grades and thus, it was not 
possible to investigate whether the higher grades (grade 3 and grade 4) showed a 
convincing trend of an increased probability of thinning in the skin thickness.  
 
It is also possible that other factors such as the age, chemotherapy and surgery of the 
patients may have influenced the results. However, Turesson 1976 studied 402 breast 
cancer patients who received radiotherapy and were followed up for ten years. 
Prognostic factors for acute and late skin reactions such as treatment-related variables 
and patient-related variables were analyzed. They could not verify that age; hemoglobin 
level, smoking and collagen vascular diseases had significant influence on the acute and 
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High frequency ultrasound provides easy, low cost and quantitative value in studying 
skin thickness in acute and chronic skin reactions. A great attention to the ultrasound 
technique must be given. It is important to maintain the ultrasound beam perpendicular 
to the surface of the skin to avoid artifacts due to scattering and minimizing variations in 
pressure of the transducer on the skin which may alter its apparent skin thickness. In this 
study, each marked point was only measured once and may have affected the intra-rater 
variability. An average measurement of two to three times would be more representative 
of each of the measured point. However, Agner 1992
 
reported that the coefficient of 
variation of repeated ultrasound measurements were low (approximately 2.2% on 
normal skin).  
 
Further prospective studies are required in measuring ultrasonic skin thickness before, 
during and after radiotherapy treatment followed-up yearly after treatment for about 10 
years to document quantitative skin changes. Warszawski 1998 proved that the structural 
changes in the assessment of early and late skin reactions can be recorded by ultrasonic 
evaluation and much earlier than visible reactions by the naked eye of the examining 
physicians. However, results did not demonstrate any significant difference in skin 
changes over long periods.  
 
Patients requiring radiotherapy had a higher rate of expander implant breast 
reconstruction failure and complications to patients who did not receive RT [Krueger et 
al 2001].  This can be explained in part by increased thinning of the skin post 
radiotherapy which increased overall contracture failure rate and thus, adverse cosmetic 
outcome.  
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Further studies are needed to confirm this explanation by quantifying the changes of the 
water and collagen in post irradiated skin. Two directions may be considered in future 
investigations to study how the severity of fibrosis affects skin thickness. One is to 
conduct biochemical or histological examinations directly to quantify the level of skin 
fibrosis and the other is to measure specifically the physical properties such as elasticity 
of the skin layer, as an indicator of the cutaneous fibrosis before and after radiation. This 
leads us to our next study which looks at histological changes of human skin cells after 
fractionated radiotherapy in an effort to explain the effects of fibrosis and skin changes 
in postmastectomy radiotherapy.   
 
4.5. CONCLUSION:  
Our study has proven that high frequency ultrasound can be utilized to document 
quantitative sonographic changes of the skin thickness in postmastectomy breast cancer 
patients following radiotherapy. This study also demonstrated a statistically significant 
difference in the skin thickness between the irradiated side and the contra-lateral non-
irradiated breast.  This finding might be helpful to predict late skin reactions. In spite of 
just using two grades of CTC scoring in this study, a statistically significant 
predisposition to chronic reactions was found in patients with acute radiation reaction. 
The ability to successfully predict the complication risk for individual patients can lead 
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5.1. INTRODUCTION: 
Radiation therapy (RT) is a commonly utilized modality for the treatment of breast cancer. It is 
routinely employed in breast conservation therapy.  Its role as adjuvant therapy in selected 
patients undergoing mastectomy for stages I and II disease is currently evolving, and has 
become an essential component of the combined modality approach for stage III disease.  
Postmastectomy Radiotherapy (PMRT) to the chest wall and to the regional lymphatics has 
shown to decrease locoregional recurrence and increase survival for women with large tumors 
and/or node-positive disease [Overgaard et al 1999, Ragaz et al 1997].  However, the risk of 
toxicity to skin and cosmesis must be weighed against local and regional recurrences.  
 
A review of literature suggests that the risk of radiation induced skin damage is affected not 
only by individual variations in response to radiation, but also by the total dose received and 
fractionation [Turesson 1990, Turesson et al 1996, Tucker et al 1992, Bernier et al 1998, Rojas 
et al 1989]. Recent years have seen the introduction of changes in radiotherapy schedules from 
conventional radiotherapy at 50Gy at 1.8 to 2Gy per week to more aggressive schedules such 
as unconventional protocols [Vicini et al 2001].  Changes in radiotherapy practice over the 
years are due to the recognition of the importance of fraction size, fraction number, total dose 
and overall time for both tumour and normal tissue reactions.  However, there is very limited 
knowledge on the extent of radiotherapy dose and fractionation schedules in inducing cellular 
radiation response in the human skin.   
 
 
The practice of radiotherapy would also greatly benefit from the discovery of biomarkers that 
correlate with symptoms and side effects pertaining to tissues within the irradiated volume.  
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Direct or surrogate biomarkers of radiation induced toxicity could potentially give clinicians 
the ability to use this information to individually plan patients treatments, develop Phase I trials 
with molecular targeted agents in combination with RT with more confidence regarding 
potential side effects and/or to intervene and reduce late effects with novel therapies directed 
against the signalling pathway(s) involved in the late injury [Jager et al 2002, Menard 2006]. 
However, the studies to date are limited and there is a rather weak correlation between the in-
vitro and clinical data.  The role of cytokines and apoptotic markers as biomarkers of radiation 
response to different radiation dose and fraction size has also never been studied.  
 
In summary, this study aims to (1) look at radiation induced apoptotic cell death in human skin 
cells after exposure to postmastectomy treatment regimes and its relation to radiation fraction 
size.  This study also (2) explores the proteomic expression of human skin cells as biomarkers 
for radiation response.   
 
5.2. MATERIAL AND METHODS 
 
5.2.1. BIOPSIES AND IRRADIATION 
 
Breast skin biopsies were obtained from a single individual and divided into small pieces of 3 
cm each, and were placed into 5 batches (Batch A, B, C, D and E). Each batch underwent a 
different radiotherapy treatment regimen, each receiving a total dose of 50Gy.  The human skin 
cell sections are irradiated daily and after each irradiation, one sample from each batch will be 
removed and stored in -80°C freezer for biochemical analysis.   
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Table 5.1: Experimental design  
Batch  Nos. of flasks Dose per fraction Duration 
A- conventional 25  2.0 Gy  25 fractions 
B  20  2.5 Gy 20 fractions 
C  10  5.0 Gy 10 fractions 
D  5 10.0 Gy 5 fractions 
E 1 50.0 Gy 1 fraction 
F- control 1 No radiation - 
*Each batch of skin tissues were irradiated under different radiotherapy treatment regimen, each receiving a total 
dose of 50Gy.  Each experiment was repeated three times and average readings obtained. 
 
The human skin cell sections are irradiated using a Gammacell irradiator (GC-40e MD 
Nordian, Canada) under different radiotherapy treatment schedules.  Following irradiation, the 
skin sections were collected, fixed in 10% phosphate-buffered formalin for 10 hours at 4 C, 
dehydrated in ascending concentration of (50%, 70%, 80%, 95% and 100%) ethanol solution 
(Merck) for 45 minutes each. This was followed by two incubations in xylene (Merck) solution 
for 15 minutes each. Samples were then placed onto plastic cassettes and transferred into 60°C 
liquid paraffin tank (Leica) for 30 minutes. Samples were embedded and left to solidify on the 
-5°C cold plate. The sections were cut into 3 µm thickness using a microtome (Leica) and 
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5.2.2. MEASUREMENT OF RADIATION INDUCED APOPTOTIC 
KERATINOCYTES  
 
5.2.2.1. Hematoxylin and Eosin (H&E) staining 
Apoptotic cells are morphologically distinct due to cell shrinkage and nuclear condensation 
that stain darker by Haematoxylin and Eosin (H&E).  Based on these criteria, irradiated 
sections were stained with H&E and apoptotic cells were counted. 
 
5.2.2.2. TUNEL assay 
DeadEnd 
TM
 Fluorometric TUNEL System (Promega, Madison, WI) was used to detect 
apoptotic cells in tissue samples following manufacturer’s protocol with some modifications.  
In brief, tissue sections after deparaffinization and rehydration were permeabilized with 
Proteinase K (30 µg/mL) solution, repeated fixation and wash steps.  After equilibration, 
nucleotide mix and rTdT enzyme were added and DAPI nuclear staining dye was applied as 
counterstaining.  The slides were mounted with cover slides and observed under x400 
magnification for TUNEL-positive cells. 
 
5.2.3. IMMUNOHISTOCHEMISTRY (IHC) ANALYSIS OF APOPTOTIC 
BIOMARKERS 
 
5.2.3.1. Histological procedures 
Serial paraffin sections of irradiated skin were dewaxed in xylene and then hydrated in 
descending concentrations of ethanol. Antigen retrieval was done by immersing the slides in 
0.01 M Tris /0.001M EDTA buffer (pH9.0) and pressure cooked for 5 minutes.  
Chapter Five - Human epidermal keratinocytes death and expression of protein markers of 
apoptosis after ionizing radiation exposure  
 
Page | 86  
 
All sections were cooled under running tap water for 10 minutes. The Dako Envision+ kit was 
used for subsequent IHC steps. Briefly, endogenous peroxidase was blocked using 3% H2O2 
for 30 minutes and washed in TBS-Tween 20 for 3 times. Non-specific binding was blocked 
using the Dako Protein Block, serum-free, for 5 minutes, followed by washes in TBS-Tween 
20 for 3 times. Subsequently, sections were incubated with monoclonal anti-active p53 (Dako 
and BD Transduction Lab), PCNA (Santa Cruz) and P21 (Santa Cruz), in dilutions of 1:500 
overnight.  
 
Table 5.2: List of antibodies used in immunohistochemistry procedures 
  Antibodies Product Code Company Clone 
Primary p53 P21020 BD Transduction 
Laboratories 
Monoclonal 
 p53 D0-7 Dako Monoclonal 
 PCNA SC-56 Santa Cruz Monoclonal 
 p21 sc-817 Santa Cruz Monoclonal 
     
Secondary Mouse IgG, HRP-conjugated,  Dako Polyclonal 
 Mouse IgM, HRP-conjugated,  Dako Polyclonal 
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After washing in TBS-Tween 20 for 3 times, the slides were incubated in secondary mouse 
antibody from Dako Envision+ kit for 1 hour. The slides were washed sequentially and 
incubated with DAB (3,3-diaminobenzidine) for 5 minutes. Subsequently, slides were 
counterstained with Gill’s III hematoxylin, dehydrated in ascending concentrations of ethanol, 
and cleared in xylene. Finally the sections were mounted using Depex (Merck).  Non-
immunised mouse antibody (IgG) was used for negative controls.  
 
Briefly, tissue sectioned were screened under the microscope and evaluated under high power 
field (hpf, x 200).  The stainings were visualized with an Olympus light microscope. 
 
5.2.3.2. HISTOPATHOLOGICAL EVALUATION 
Sections of immunostained skin were evaluated under the microscope by an experienced 
pathologist (Singapore General Hospital, Singapore).  The epidermal area in each biopsy 
sample was measured and both total and specifically stained keratinocyte nuclei were 
evaluated and counted.  Since the number of positive cells was low in the irradiated tissue, we 
use the entire tissue section as reference determining the total number of keratinocyte nuclei.  
The difference between nonimmunoreactive (control) and immunoreactive (irradiated) 
keratinocyte nuclei was clear cut and cells were scored and the differences counted.  The 
staining values are expressed as percentage of positive cells of the total number of 
keratinocytes evaluated with the control as a reference.  
 




Chapter Five - Human epidermal keratinocytes death and expression of protein markers of 
apoptosis after ionizing radiation exposure  
 
Page | 88  
 
Table 5.3:  The staining intensity and pattern was evaluated using the scale below 
Staining Pattern Score 
No Staining at all, or membrane staining in less than 10% of 
the cells 
0 
A faint/barely perceptible membrane staining is detected in 
more than 10% of the cells.  The cells are only stained in part 
of their membrane 
1+ 
A weak to moderate staining of the entire membrane is 
observed in more than 10% of the cells 
2+ 
A strong staining of the entire membrane is observed in more 
than 10% of the cells 
3+ 
 
5.2.5. WESTERN BLOT ANALYSIS OF APOPTOTIC BIOMARKERS 
 
5.2.5.1. Protein extraction from tissue culture cells 
Skin tissues were minced and lysed directly in cell lysis buffer containing 20 mM Tris-HCI (ph 
7.5), 1% Triton X-100, 100 mM NaCL, 0.5% Nonide P-40 and I mg/ml protease inhibitor 
cocktail.  (Boehringer Mannheim, Mannheim, Germany).  Cells were solubilized by passing 
solution through the pipette tip repeatedly followed by incubation on ice for 15 minutes. 
Samples were then centrifuged at 4°C, 12,000g for 10 minutes and the supernatant containing 
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5.2.5.2. Determination of protein concentrations 
Protein concentration of cell lysates (CLs) was determined using Bradford protein 
quantification methods according to manufacturer’s instructions. A standard curve was 
prepared using bovine serum albumin (BSA) with concentrations ranging from 0-2000 μg/ml 
the lysis buffer. Five and ten fold dilutions were carried out for each sample and 4 repeats were 
done for each standard or sample. 200μl of colorimetric assay reagent was added to each well. 
After the 96-well plate was incubated at 37°C for 30 minutes, protein concentrations were 
assayed by measuring absorbance at 570 nm with a reference wavelength of 690nm, using a 




5.2.5.3. SDS-polyacrylamide gel electrophoresis (SDS-Page) 
Sodium Dodecyl Sulphate (SDS)-polyacrylamide protein separations were performed using the 
Protean II or III system (BIO_RAD). The separation gels (8% and 12%), depending on the 
molecular weight of the protein of interest as well as stacking gels were cast according to the 
composition shown in Table 5.4. After the gels were solidified, the comb was removed from 
the stacking gel and the wells rinsed by de-ionised H2O (dH2O). Samples containing 20 to 
60μg of protein were mixed with SDS-PAGE loading buffer (Table 5.5), boiled for 5 minutes 
at 95°C and cooled down on ice immediately to prevent renaturation of proteins. Subsequently, 
these samples were loaded into individual wells of the stacking gel. 10μl of protein standards 
(BIO-RAD) was loaded in one lane for each run. Gels were run at an initial 80 volts past the 
stacking gel after which voltage was increased to 120 volts in running buffer using a PowerPac 
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12% separation gel (20ml) 
30% Acrylamide 1.4ml 5.3 8 
10% SDS 100μl 200μl 200μl 
10% Ammonium 
Persulfate (APS) 
100μl 100μl 100μl 
TEMED 10μl 10μl 10μl 
1.5M Tris/HCl pH 6.8 2.5ml - - 
0.5M Tris/HCl pH 8.8 - 5ml 5ml 
50% glycerol - 1ml 1ml 
dH2O 6ml 5ml 2.5ml 
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Table 5.5: Composition of self-prepared reagents for western blotting 
Reagent Composition 
SDS-PAGE loading buffer 
2% SDS, 0.01% bromophenol blue, 10% 
glycerol, 100mM DTT 
Running buffer 25mM Tris, 192mM Glycine, 0.1%SDS 
Transfer buffer 10mM Tris, 75mM Glycine, 10% methanol 
Tris buffered saline (TBS) 10mM Tris, 150mM NaCl 
TBST or Wash buffer TBS with 0.1%(v/v) Tween 20  
Blocking buffer 5% (w/v) skimmed milk in TBST 
Incubation Buffer 1% (w/v) skimmed milk in TBST 
 
5.2.5.4. Protein electroblotting (Protein transfer) 
Nitrocellulose membrane, blot absorbent filter papers and sponges (all from BIO-RAD) were 
pre-soaked in transfer buffer. The gel with the separated proteins from the “SDS-PAGE” 
casing was transferred onto the nitrocellulose membrane in the sandwich conFigureuration 
shown in the transfer stack (Figure 5.1). Care was taken to avoid bubbles during the stacking. 
The entire assembly was placed in the gel tank with transfer buffer and protein electroblotting 
(transfer) performed at 250mA for 120 minutes in a cold room. After the run was completed, 
the nitrocellulose membrane was stained with Ponceau (Sigma) to ensure proper and complete 
transfer. 
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5.2.5.5. Blocking, antibody incubation, washing and stripping 
Equal amounts of protein samples were denatured, separated by 12% SDS-PAGE and 
transferred onto nitro-cellulose membrane by semi-dry blotting.  The membrane was placed 
protein side up and incubated for 2hrs in blocking solution.  
 
Primary antibodies were diluted in 5% milk and incubated with the membrane for 2hrs at room 
temperature. Secondary antibodies were diluted in 5% milk and incubated with the membrane 
for 1hr at room temperature. Following primary and secondary antibody incubations 
membranes were washed 5 times each time 10 minutes with 30ml washing buffer and 
incubated in sufficient volume of buffer diluted with horseradish peroxidase (HRP)-coupled 
secondary antibody at room temperature for 1 hour. The membrane was washed again with 
washing buffer for 5 times before incubation with Western lightning plus-ECL (Perkin Elmer) 
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Table 5.6 List of antibodies used in Western Blot Analysis 
  Antibodies Product Code Company Clone 
Primary p53 P21020 BD Transduction Laboratories monoclonal 
 
PCNA SC-56 Santa Cruz monoclonal 
 




5.2.6. COMPUTERIZED GEL DENSITOMETRY 
A Bio-Rad gel scanner and densitometer program (Gel-Pro ® Analyzer version 4.5: 
MediaCybernetics, Maryland, USA) was used to assess concentrations of the bands obtained 
by Western blots.  There were measured as total density units. 
 
 
5.2.7. STATISTICAL ANALYSIS 
Statistical Package for Social Sciences (SPSS), version 17.0 was the statistical tool used for 
data analysis. Nonparametric methods were used for the statistical analysis using one-way 
Anova (Analysis of Variance) - or Student’s t-tests.  A value of P<0.05 was considered to be 
statistically significant. 
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5.3.1. RADIATION INDUCED APOPTOTIC KERATINOCYTE CELL DEATH IS 
DOSE AND FRACTION SIZE DEPENDENT 
 
5.3.1.1. Increased Apoptotic Keratinocyte Cell Count: 
Since it has been proposed that keratinocytes damaged by ionizing irradiation undergo 
apoptosis, we analysed the expression of apoptotic cells in the skin tissues of the volunteer 
using H&E staining and TUNEL assay. The skin tissues were irradiated with different dose and 
fractionation schedules.  (Table  5.7 & 5.8) 
 
Table 5.7: Percent of radiation induced apoptotic cells from H&E and TUNEL staining 
Dose 2Gy 2.5Gy 5Gy 10Gy 50Gy 
H&E 7.4 
(5.2 to 9.6) 
9.0 
(8 to 1) 
26.75 
(20.43 to 33.07) 
39.0 
(37.09 to 40.91) 
57.82 
(49.34 to 66.3) 
TUNEL  23 
(10 to 35) 
28.5 
(19 to 38) 
45.2 
(40.3 to 50.1) 
75.0 
(65.69 to 81.31) 
83.3 
(78.8 to 87.8) 
*The mean percentage (including 95% confidence interval CI) of H&E and TUNEL positive cells is shown.  A 






Table 5.8: Correlations between different radiation fractionation and TUNEL staining 
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10Gy 2Gy Day 5 2.5Gy Day 4 5Gy Day 2 10Gy Day 1  0.49 <0.000 
 
30Gy 2Gy Day 15 5Gy Day 6 10Gy Day 3   0.62 <0.000 
 
50Gy 2GyDay 25 2.5Gy Day 20 5Gy Day 10 10Gy Day 5 50Gy Day 1 0.73 <0.000 
        
*Nonparametric correlations of TUNEL positive cells with different radiation fractionation are calculated.  Both 
Pearson’s coefficient of correlation (rp) and the corresponding P value are shown.  All statistical tests are two-
sided. In all groups, there was a statistically significant correlation between TUNEL positive cells and dose size 
fractionation.   
 
Radiation induced the formation of apoptotic cells and a noticeable increase was observed in 
skin tissues that received higher radiation dosage.  These findings were confirmed by TUNEL 
assay.  There is also a significant (p<005) and strong correlation of apoptotic cells with 
increased fraction size. 
 
5.3.1.2. Morphological changes of radiation induced apoptotic keratinocytes  
Results showed that radiation is mostly absorbed by the epidermal layers and observed to 
damage the epidermal keratinocytes leading to apoptosis.  These cells had characteristic 
dyskeratotic apoptotic cells with pyknotic nuclei in the irradiated sections. HE staining on 
control sections demonstrated normal epidermal morphology (Figure 5.2) while irradiated 
sections demonstrated strong evidence of cellular damage caused by ionizing radiation (Figure 
5.2B-D).   
 
 
Figure 5.2. Morphological evaluation 
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The keratinocytes were enlarged with cytological atypia Figure 5.3. The epidermis in the 
irradiated skin was thin, containing only one to three layers of keratinocytes and in some 




           
Figure 5.3 shows morphological changes in cell after       Figure 5.4. HE slide showing a detached epidermis 






A detached epidermis layer due to 
irradiation 
Cells showing cytological atypia 
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5.3.2. EXPRESSION OF APOPTOSIS RELATED PROTEIN MARKERS WITH 
INCREASING RADIATION DOSE 
 
 5.3.2.1. Accumulation of p53, PCNA and p21 proteins with increasing dose 
We analyzed sections of paraffin-embedded skin biopsies of the volunteer for p53, PCNA and 
p21 apoptotic related marker proteins using western blot and immunohistochemistry analysis.  
Hardly any apoptotic positive cells were seen in the control epidermis before radiation.   
 
Skin tissues were irradiated with 2, 2.5, 5, 10 and 50 Gray. Apoptotic proteins (PCNA, P21) 
were confirmed to be up-regulated in radiation exposed skin cells as compared to normal skin 
cells with no radiation.   There is strong correlation of apoptotic protein expressions with 
increased radiation dosage. (Table 5.9) 
 
Table 5.9: Apoptotic protein expression in different radiation dosage starting from 2 – 50Gy 
 Value (95% CI) 
Proteins 2Gy 2.5Gy 5Gy 10Gy 50Gy 
PCNA 14.0 
(10.71 to 17.29) 
18.0 
(12.61 to 23.39) 
27.0 
(20.43 to 33.57) 
44.0 
(37.09 to 50.91) 
75.0 
(68.69 to 81.31) 
P21 22.5 
(18.28 to 27.2) 
41.0 
(28.18 to 53.82) 
60.0 
(49.34 to 70.66) 
75.0 
(68.92 to 81.08) 
83.0 
(77.11 to 89.82) 
P53 16.0 
(11.94 to 20.06) 
25.0 
(15.31 to 34.67) 
30.0 
(24.16 to 35.84) 
44.0 
(37.09 to 50.91) 
7.0 
(5.15 to 8.85) 
*The mean percentage (including 95% confidence interval CI) of PCNA, P21 and P53 immunoreactive cells is 
shown.  A statistically significant difference (p<0.05) was found in the apoptotic protein expression and radiation 
dosage.  
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Statistical analysis with ANOVA revealed a significant increase of PCNA and p21 expression 
with increased radiation dosage. (p<0.05).  Immunohistochemically, 14 % (range 10.71% to 
17.29%) of the keratinocytes were positive for PCNA and 22.5% (range 18.28% to 27.2%) for 
p21 after 2Gy of irradiation. The most widespread, intense and uniform staining for PCNA and 
p21 was observed in skin that had received 50Gy of irradiation.  After radiotherapy was 
completed, 75% (range 68.69% to 81.31%) of keratinocytes were PCNA positive and 83%  
(range 77.11% to 89.82%) were p21 positive. In most cases, 64% or more of the keratinocytes 
(score 2.9) showed a moderate to strong intensity for PCNA staining and 81%  (score 3.3) for 
p21. 
 
Figure 5.5. The boxplot for PCNA immunoreactitivity in different radiation dosage starting from 2Gy to 50Gy.  
Bars represent the range within the different radiation dosage as indicated. 
 
PCNA 
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Figure 5.6. The boxplot for p21 immunoreactitivity in different radiation dosage starting from 2Gy to 50Gy.  Bars 
represent the range within the different radiation dosage as indicated. 
 
In contrast, P53 expression started to increase after 2Gy of radiation up to a maximum dose of 
10Gy.  At 2 Gy, a higher number of cells faintly positive for p53 extended from the suprabasal 
layer to the stratum granulosum.  At more superficial locations, these cells became strongly 
stained by anti-p53.  The maximum expression of p53 (median =44%, range 37.09% to 
50.91%) was reached at 10Gy after irradiation exposure, and in most cases the p53 
immunoreactivity appeared to be concentrated within the keratinocyte nuclei.  At higher 
radiation dosage (> 10Gy), the epidermal sections showed a downward trend in the expression 
of P53. The irradiated keratinocyte nuclei appeared to be p53 negative or only faintly stained at 
50Gy (median=7% , range 5.15% to 8.85%).  Western blot analysis revealed similar results. 
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Figure 5.7. The boxplot for p53 immunoreactitivity in different radiation dosage starting from 2Gy to 50Gy.  Bars 
represent the range within the different radiation dosage as indicated. 
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5.3.3. MORPHOLOGICAL CHANGES OF PCNA, P21 AND P53 WITH 
INCREASING DOSE 
Results unequivocally demonstrated that, in response to DNA damage, PCNA and p21 are up-
regulated for cell cycle arrest to facilitate DNA repair 
 
 
Figure 5.8  Dose series of Irradiated skin.  Sections were stained with monoclonal anti-PCNA 
A-Control, B- 2Gy, C-5Gy, D-10Gy, E-50Gy 
 
 
Figure 5.9  Dose series of Irradiated skin.  Sections were stained with monoclonal anti-p21 
A-Control, B- 2Gy, C-5Gy, D-10Gy, E-50Gy 
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As for p53, we hardly detected any cells stained with anti-p53 antibody in the control slide.  
P53 expression started to increase after 2Gy of irradiation and maximal expression of p53 was 
reached at 10Gy.  Thereafter irradiated cells appeared to be p53 negative or only faintly stained 
at 50Gy.  
 
 
Figure 5.10  Dose series of Irradiated skin.  Sections were stained with monoclonal anti-p53 
A-Control, B- 2Gy, C-10Gy, D-50Gy 
 
5.3.4. Accumulation of p53, PCNA and p21 proteins with increasing fraction size 
Subsequently, we tested by immunohistochemistry the expression of marker proteins of 
apoptosis, namely p53, P21 and PCNA with different radiation fractionations. 
 
Repeated measures of ANOVA revealed that the effects of different radiation fractionation 
(2Gy, 2.5Gy, 5Gy, 10Gy and 50Gy) on human skin cells were significantly different from each 
other (p<0.05).  There is a positive and significant correlation (Pearson’s correlation r) between 
radiation fractionation and apoptotic protein expression (PCNA, p21 and P53), measured at 
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10Gy 2Gy Day 5 2.5Gy Day 4 5Gy Day 2 10Gy Day 1  0.59 <0.000 
 
30Gy 2Gy Day 15 5Gy Day 6 10Gy Day 3   0.61 <0.002 
 
50Gy 2GyDay 25 2.5Gy Day 20 5Gy Day 10 10Gy Day 5 50Gy Day 1 0.66 <0.000 




















10Gy 2Gy Day 5 2.5Gy Day 4 5Gy Day 2 10Gy Day 1  0.657 <0.000 
30Gy 2Gy Day 15  5Gy Day 6 10Gy Day 3  0.523 <0.002 
50Gy 2GyDay 25 2.5Gy Day 20 5Gy Day 10 10Gy Day 5 50Gy Day 1 0.634 <0.000 
        
*Table 5.10 & 5.11: Nonparametric correlations of PCNA and P21 immunoreactive cells with different radiation 
fractionations are calculated.  Both Pearson’s coefficient of correlation (rp) and the corresponding P value are 





Figure 5.11-5.13 The boxplots for PCNA protein expression to different radiation 
fractionation for a dose of 10Gy, 30Gy and 50Gy 
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Figure 5.11 Boxplot for PCNA at 10Gy delivered to human skin at different fractionation (2Gy in 5 fractions, 
2.5Gy in 4 fractions, 5Gy in 2 fractions  and 10 Gy in a single fraction) 
 
Figure 5.12 Boxplot for PCNA at 30Gy delivered to human skin at different fractionation (2Gy in 15 fractions, 
5Gy in 6 fractions  and 10 Gy in 3fractions 
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Figure 5.13 Boxplot for PCNA at 50Gy delivered to human skin at different fractionation (2Gy in 25 fractions, 2.5 
Gy in 20 fractions, 5Gy in 10 fractions , 10 Gy in 5 fractions and 50 Gy in a single fraction) 
 
Figure 5.14-5.16 The boxplots for p21 protein expression to different radiation 
fractionation for a dose of 10Gy, 30Gy and 50Gy 
 
Figure 5.14 Boxplot for P21 at 10Gy delivered to human skin at different fractionation (2Gy in 5 fractions, 2.5Gy 
in 4 fractions, 5Gy in 2 fractions and 10 Gy in a single fraction) 
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Figure 5.15 Boxplot for P21 at 30Gy delivered to human skin at different fractionation (2Gy in 15 fractions, 5Gy 
in 6 fractions and 10 Gy in 3 fractions) 
 
Figure 5.16 Boxplot for P21 at 50Gy delivered to human skin at different fractionation (2Gy in 25 fractions, 
2.5Gy in 20 fractions, 5 Gy in 10 fractions, 10 Gy in 5 fractions and 50 Gy in a single fraction) 
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In summary, we have checked for associations between cytokine expression, radiation dose 
and type of fractionation regimen, given that both radiation and proteins expression are 
important variables in mediating radiation response.  Results have shown that PCNA and p21 
levels were significantly associated with dose and treatment regimen, while elevation of p53 
was significant only up to 10Gy.  These results were supported by western blot findings. 
 
5.3.5 WESTERN BLOT ANALYSIS REVEALED ELEVATED LEVELS OF PCNA 
AND P21 PROTEINS IN IRRADIATED KERATINOCYTES AND THIS IS DOSE AND 
FRACTION SIZE DEPENDENT 
 
Little or no immunoreactive band specific for p53, PCNA and p21 protein was observed in the 
lysates of non-irradiated control keratinocytes.  Irradiated cell lysates revealed an accumulation 
of p53 protein which was detected at 2Gy and peaked at 5Gy.  After 5Gy, the expression level 
slightly declined and was not detectable at 50Gy. 
 
          β – Actin  
Figure 5.17  Little or no immunoreactive band specific for p53 was observed at dose above 10Gy 
 
Regarding p21 and PCNA, a weak band was seen in control keratinocytes.  Overexpression of 
p21 and PCNA protein was seen which increases with radiation dosage and fractionation. 
Chapter Five - Human epidermal keratinocytes death and expression of protein markers of 
apoptosis after ionizing radiation exposure  
 
Page | 108  
 
  
Figure 5.18 and 5.19  Western blot analysis of p21 and PCNA protein with increasing radiation dosage 
 
Figure 5.20 and 5.21  Western blot analysis of P21 and PCNA reveals a higher level of protein with increasing 
fraction size at 10Gy 
 
β- actin 
β - actin 
β - actin 
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Figure 5.22 and 5.23 Western blot analysis of P21 and PCNA reveals a higher level of protein with increasing 
fraction size at 50Gy 
 
5.4 DISCUSSION 
Radiation induced injury is a multicellular process [Bentzen 2006] (Figure 5.24).  Cellular 
damage caused by the ionizing radiation induces production and recruitment of specific 
biomarkers involved in DNA repair, cell death, inflammation and other pathophysiologic 
responses [Faulhaber 2005, Hagan 2004]. The altered expression of these growth factors and 
cytokines may thus result in a modulation of the cellular interactions of cell types involved for 
example, TGFβ has been shown to influence the proliferation pattern of fibroblasts, which may 
be one initial step in the onset of fibrosis [Bentzen 2006].   
 
β - actin 
β - actin 
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Figure 5.24: Bentzen  Nature Reviews Cancer 2006, 702–713 
 
As such, the practice of radiotherapy would greatly benefit from the understanding of apoptosis 
and its associated biomarkers that correlate with radiation dose and its side effects pertaining to 
tissues within the irradiated volume.  This forms the basis of our study. 
 
In this study we demonstrated dose-dependent keratinocyte apoptosis following irradiation, 
that was associated with activation of apoptosis regulating biomarkers.  We demonstrated that 
increasing radiation dosage led to increased keratinocyte death in human skin. Our results are 
in agreement with the findings of previously reported studies showing a dose related induced 
apoptosis using swine skin [Archambeau 1995 ]  and human cochlear cells [Wong et al 2006].  
Morphological evaluation was consistent with our findings.  HE staining revealed an increased 
in the number of apoptotic cells with condensed nuclei surrounded by a bright halo.  These 
morphological changes were similar to what has been described in Ponten F. 2001.  The 
keratinocytes were enlarged with cytologic atypia. 
P53 
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The relationship between the total dose of radiation and fractionation of the dose given is also 
crucial in radiotherapy with respect to the development of radiation induced effects in normal 
tissues. This elevates the therapeutic ratio and enables efficient tumour control while 
decreasing both early and late radiation effects in normal tissues [Gorodetsky 1999].  
 
This is one of the few studies that evaluated the difference in cellular response due to minor 
variations in the protocols of fractionation radiotherapy.  For the evaluation of the effect of 
changes in dose/fraction, the human skin cells irradiated with the same total dose of 10Gy, 30 
Gy and 50Gy were grouped according to the dose/fraction given.  No significant difference in 
apoptotic cell death between groups of samples irradiated by dose fraction of 2Gy and 2.5Gy 
could be detected.  However, irradiation with a higher dose/fraction of 5Gy and 10Gy resulted 
in a very significant elevation of mean % apoptotic cell death expression.  Moreover, 
significant changes were also found at much lower total dose of 30Gy, where the treatment was 
given with a high dose/fraction of about 5Gy.  Our results demonstrate that the increase in dose 
of radiation per fraction had much more impact on radiation induced apoptosis than elevation 
in the total dose, which may result in worst skin outcome [Archambeau 1995].  Our result is 
similar to previous study by Archambeau
 
1995 who evaluated the effect of changes in 
dose/fraction using a swine skin model.  Following irradiation there is a dose-dependent loss of 
basal cells.  The fields treated with 2Gy daily dose fractions show no change in the basal cell 
density until total doses of 20-25Gy are delivered.  This period is followed by increasing cell 
loss up to 50Gy and necrosis is produced.   A separate study by Gorodetsky 1999
 
looked at the 
effect of radiation fraction size on skin viscoelasticity.  They also found that the increase in 
dose of radiation per fraction greatly increased skin stiffness.  There is an intimate relationship  
between radiation-dose fractionation and clinical outcome of radiation therapy.   
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As previously discussed [Faulhaber 2005, Hagan 2004], cellular damage caused by ionizing 
radiation induces production and recruitment of specific proteins that have the potential to 
predict radiation induced toxicity in tissues within the irradiated volume. Our interest in these 
proteins expression during Radiation Therapy is based in part on Rubin 1995
 and colleagues’ 
description of a cytokine-linked continuum of early and late radiation responses. Rubin et al 
showed in murine and clinical lung models that radiation induced fibrosis is progressive after 
treatment and begins immediately following lung irradiation.  Levels of IL-1, TGF beta and 
TNF alpha were observed to increase in lung tissue immediately after radiation exposure, 
however clinically appreciable lung fibrosis may occur months later.  A number of clinical 
studies have also shown that cytokines are elevated during and after Radiotherapy for a variety 
of malignancies [Menard 2006, Okunieff 2008, Kovacs 2003].  Using this as a feasibility 
study, we measured the protein levels of p53, PCNA and p21 in human breast skin cells after 
receiving postmastectomy radiotherapy treatment regimens as biomarkers for radiation 
response.  The radiation response of cytokines within a controlled population with the same 
dose but in different fraction size has never been studied before.  Thus this is one of the first 
studies of its kind on cytokines expression in human breast skin after exposure to fractionated 
radiation.  
 
Statistical analysis with ANOVA revealed a significant increase of PCNA and p21 expression 
with increased radiation dosage (p<0.05) and with different radiation fraction size  (p<0.05). 
Our results have shown that cytokines are up-regulated in response to radiation; and this is 
dependent on radiation dosage and fraction size. This is in agreement with previous studies that 
showed these cytokines are radiation-inducible cytokine. Ponten F 2001 investigated levels of  
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p53 and p21 in skin exposed to different types of radiation. Results show an early onset of 
increased p53 levels and a correlation between p53 and p21 was evident.   In other studies, 
p53, PCNA and p21 were induced in hairless mouse epidermis following UVB radiation 
[Mallikarjuna 2005], human skin response to x-ray treatment with release of p53 [Mab 2003] 
and  induced expression of p21 and PCNA proteins in UVB irradiated human epidermis 
[Nazim et al 1999] . However, drawbacks of these studies were the use of mice epidermis and 
UVB radiation and included a range of radiation dose.  In our study, these factors were closely 
controlled.   
 
Results from our studies show predictable patterns of cytokine expression.  PCNA and P21 
levels elevated gradually from 2Gy to 10Gy, followed with a sharp increase at 50Gy. On the 
other hand, p53 was elevated at 2Gy and persisted until 10Gy, and then returned to baseline 
values.  This pattern was also consistent with increasing fraction size. Not only did this study 
demonstrate the early and persistent elevation of cytokine production following irradiation, but 
it also determined consistent patterns of cytokines expression.   A similar pattern of cytokine 
expression was observed in murine studies.  Rubin 1995 and colleagues studied cytokine 
induction in mice receiving thoracic irradiation. They found several cytokines were 
longitudinally elevated with consistent patterns between mice.   
 
One question arising from our results is why p53 did not exhibit similar pattern with PCNA 
and p21 given that all are apoptotic inducing cytokines.  P53 plays a crucial role in the 
protection against DNA damage allowing cell cycle arrest, DNA repair or apoptosis by 
transcriptional activation of p53 related genes such as p21 and Bax [Murphy 2002]. Ionizing 
radiation produces double and single strand DNA breaks.  Cells respond to DNA 
photoproducts and DNA breaks by accumulation of functionally active p53 proteins. 
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Upon exposure to radiation, p53 is known to sense DNA damage and to subsequently halt the 
cell cycle in the G1 phase, providing time for DNA repair.  If the damage to the genome is too 
serious and repair likely to fail, p53 acts as an inducer of apoptosis [Ponten F 2001].  
Consistent with this report, we observed that these proteins are upregulated in response to 
irradiation-caused DNA damage leading to cell cycle arrest to allow enough time for DNA 
repair.  This observation is consistent with similar study in animal model showing stimulatory 
effect of UV radiation on the protein levels of p53 and downstream effector p21 [Kovacs 
2003].  In a separate time-dose study  by Peter Mab et al 2003 human skin was exposed to 
UVB radiation and p53 expression was detected.  P53 expression started to increase 3h after 
irradiation and reached a maximum at 12 h after UVB exposure.  However, epidermal sections 
at 36 h appeared to be p53 negative or only faintly stained.  This seem to suggest p53 has a 
short half life of less than 24h and is time -dose dependent.  However, more studies are needed 
in the future to further support this anticipation, Further in this study, the radiation induced p21 
protein was detected much sooner than PCNA, correlating well with the expression of p53.  It 
seems likely that up regulation of p21 could have been mediated via p53 pathway by 
irradiation.  The different time course of the expression also supports this hypothesis. 
 
PCNA is implicated in DNA replication and repair by forming a sliding platform that could 
mediate the interaction of numerous proteins with DNA [Warbrick 2000]. It is known that p21 
binds to PCNA and inhibits PCNA function in DNA replication [Fotedar et al 2004] . 
Therefore PCNA is regarded as an important target for p21 as well as reliable biomarker for 
cell proliferation. It has been observed that p53/p21 signal transduction pathway plays a 
significant role in the regulation of the PCNA response to ionizing radiation [Wenz 1998] .   
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In view of the high affinity of PCNA to DNA strand breaks due to the ionizing radiation 
[Moggs et al 2000],  it is logical to expect the rapid recruitment of PCNA to ionizing radiation 
induced strand breaks.  In this study, we have demonstrated the induction of PCNA after 
radiation in human skin cells and this induction is dose and fraction size dependent. 
 
The evidence from our study and clinical literature demonstrate a significant dose and fraction 
size response during RT. They also support the molecular rationale that increased cytokines 
expression may serve as indicators of increased normal tissue toxicity.   
 
The clinical research environment presents a number of unique challenges to prospective 
proteomics studies from sample collection to processing, storage and analysis.  There are many 
sources of error (delays in sample collection or processing, misinterpretation of standard 
operating procedures (SOP) and so on) that can introduce a myriad of confounding variables, 
which in turn will render the resulting proteomic data inconclusive.  We have considered these 
issues in details and study designs were carefully drawn out to minimize the influence of 
extraneous environmental factors that may affect our conclusions from these data.  In addition 
our principal data were derived from a single volunteer, thus avoided interindividual variations 
in the responses to DNA damage. 
 
Another limitation of our work is the small sample size and limited apoptotic markers 
identified in skin relating to postmastectomy radiotherapy.  Future studies with bigger sample 
sizes are warranted to determine the cytokine changes after radiation exposure and how these 
relate to normal tissue radiation toxicity with greater certainty. 
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In summary, our results demonstrate the specific up-regulation of a number of apoptotic related 
marker proteins after irradiation and suggest that premature keratinocyte elimination occurs via 
apoptosis.  Results also demonstrated that their increased expression or activation occurs in 
relation to radiation dose and fraction size.  While total dose is critical in determining the 
severity of skin toxicity, skin effects are more severe following fractionations schedules that 
employ daily dose fractions of 5Gy or higher than follow dose schedules using 2-2.5Gy daily.   
 
More importantly, based on our findings, there is a potential for the use of anti-apoptotic 
strategies which could be targeted at various regions of the apoptotic pathway to prevent 
radiation induced skin toxicity.  Access of anti apoptotic factors to the skin could possibly be 
delivered topically.  The use of such a target-specific approach would minimize the systemic 
side effects of anti-apoptotic treatments.   However, the mechanisms regulating the increase in 
cytokines in vivo in response to cellular damage and their role need additional study. 
 
Taken together, all of the experiments discussed in this study lay the groundwork for future 
larger scale clinical trials within our institution and in collaboration with other clinical centres.  
Protein markers have potential as proxy indicators of radiation sensitivity and exposure.  It is 
hoped that the preliminary work presented here will contribute to the identification of protein 
biomarkers that contributes not only to the advancement of radiation biology in the long-term, 
but allows us to make a difference in the lives of cancer patients.  The very high incidence of 
breast cancer partially attributable to the ageing of population and the increasing use of surgery 
and postoperative radiotherapy for its treatment make the above type of study of special 
interest, with the side effects of radiotherapy an increasingly important issue.   
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